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Abstract  
The   Vascular   Endothelial   Growth   Factor   family   of   proteins   are   key   regulators   of  
physiological   systems.   Originally   linked   with   endothelial   function,   they   have   since  
become   understood   to   be   principal   regulators   of   multiple   tissues,   both   through   their  
actions  on  vascular  cells,  but  also  through  direct  actions  on  other  tissue  types,  including  
epithelial  cells,  neurons,  and   the   immune  system.  The  complexity  of   the  5  members  of  
the   gene   family   in   terms   of   their   different   splice   isoforms,   differential   translation,   and  
specific   localisations  have  enabled   tissues   to  use   these  potent   signalling  molecules   to  
control   how   they   function   to   maintain   their   environment.   This   homeostatic   function   of  
VEGFs   has   been   less   intensely   studied   than   their   involvement   in   disease   processes,  
development,   and   reproduction,   but   they   still   play   a   substantial   and   significant   role   in  
healthy  control  of  blood  volume  and  pressure,  interstitial  volume  and  drainage,  renal  and  
lung   function,   immunity,   and   signal   processing   in   the   peripheral   and   central   nervous  
system.   The   widespread   expression   of   VEGFs   in   healthy   adult   tissues,   and   the  
disturbances  seen  when  VEGF  signalling  is  inhibited  support  this  view  of  the  proteins  as  
endogenous   regulators   of   normal   physiological   function.      This   review   summarises   the  
evidence  and  recent  breakthroughs  in  understanding  of  the  physiology  that  is  regulated  
by  VEGF,  with  emphasis  on  the  role  they  play  in  maintaining  homeostasis.  
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Introduction  
The  Vascular  Endothelial  Growth  Factor  (VEGF)  family  of  proteins  are  key  regulators  of  
physiological  processes   in  development,  growth,  maintenance  of   lifelong  health,  and   in  
many   disease   processes.   Although   originally   described   for   the   properties   on   vascular  
endothelial  cells  in  1989,  the  subsequent  thirty  years  of  research  have  identified  multiple  
roles  for   these  proteins   in  many  different   tissues,  and  many  pathological  states.  Of   the  
more  than  65000  publications  on  the  VEGFs  since  their  discovery,  the  vast  majority  have  
focused  on  their  role  in  abnormal  states  in  humans.  Their  role  in  development  has  also  
been   intensively   investigated   since  VEGF-­A  became   the   first   gene   to  be   identified   as  
heterozygously   lethal   when   knocked   out.   However,   right   from   the   very   beginning   of  
VEGF   research,   a   series   of   elegant   papers   from   Harold   Dvorak’s   laboratory  
demonstrated  that  VEGF-­A  was  expressed,  and  at  relatively  high  levels,  in  many  normal  
tissues  from  healthy   individuals.  Despite  this,  VEGFs  have  been  considered  to  be  very  
good  targets  for  development  of  inhibitors,  both  for  VEGF-­A  itself,  other  members  of  the  
family,   and   for   the  VEGF   receptors,   particularly  VEGF   receptor  2   (VEGFR2).  The   fact  
that   VEGF-­A   neutralizing   antibodies   were   relatively   safe   as   anticancer   agents   further  
supported   the   idea   that   VEGFs   were   disease   causing   agents   in   adults.   However,  
relatively   safe   did   not   mean   side   effect   free,   and   the   consequences   of   anti-­VEGF-­A  
therapy   (hypertension,   proteinuria,   dizziness,   pain   amongst   others)   do   reinforce   the  
concept   that   these  proteins  play  a  normal  physiological   role.   It   is  widely  accepted   that  
there   is   a   clear   and   important   role   for   VEGFs   in   embryonic,   and   fetal   development,  
growth  during  adolescence  and  in  pregnancy,  and  the  role  of  VEGFs  in  the  angiogenesis  
associated  with  ovulation   (in  particular  during  endometrial  and  ovarian  maturation,  and  
during  placentation)  has  been  widely  discussed.  There  are  therefore  areas  of  physiology  
associated   with   development   where   VEGFs   have   long   been   widely   recognised   as  
important.   However,   amongst   the   many   thousands   of   papers   describing   VEGFs   in  
disease  states  and  development  there  is  a  growing  body  of  literature  that  indicates  that  
VEGFs   play   a   physiological   role   in   normal   homeostasis   outside   that   of   the  
developmental   pathway,   and   that  disruption  of   this   role  by  either   too  much  or   too   little  
VEGF   can   result   in   pathology.   In   this   review   we   will   therefore   focus   on   how   VEGFs  
contribute   to   normal   physiology   in   adult   mammals,   and   in   particular   their   role   in  
maintaining  a  homeostatic   environment   conducive   to  healthy   function.   In  particular  we  
intend  to  discuss  the  roles  of  VEGF  in  maintaining  normal  physiological  function  through  
its  activities  as  an  angiogenic  agent,  but  also  as  a  regulator  of  vascular  permeability,  and  
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the  growing  body  of  evidence  that  it  is  a  cell  survival  factor,  a  nerve  growth  factor,  and  a  
signalling   regulator   that   plays   multiple   roles   in   healthy   systems,   as   well   as   being  
disrupted  in  disease  states.  Its  role  in  the  kidney,  the  lung,  the  nervous  system,  skeletal  
muscle,   fat,   and   the   retina   are   discussed   as   exemplars   of   where   VEGF   is   a   critical  
regulator  of  physiology.  This  is  not  exhaustive,  and  there  are  areas  we  have  not  covered  
(gut,  heart,  etc),  but  we  hope  that  this  provides  a  useful  source  to  think  about  VEGF  as  a  
key  regulator  of  normal  as  well  as  pathological  states.  
VEGFs  
The   VEGF   family   of   proteins   is   encoded   by   five   distinct   genes   in   humans   and   other  
mammals.   VEGF-­A,   the   canonical   member   of   the   family,   VEGF-­B,   VEGF-­C,   VEGF-­D  
and  Placental  Growth  factor  (PlGF)  are  each  encoded  by  multi-­exon  genes,  and  give  rise  
to   multiple   splice   variants.   They   are   all   secreted   proteins,   containing   heparin   binding  
domains,   receptor   binding   domains,   glycosylation   sites,   and   intramolecular   and  
intermolecular  cysteine  disulphide  bonds.  Each  protein  acts  a  dimer,  and  can  act  on  two  
receptor   families,   the  VEGFR  and  neuropilin   families.   VEGF  Receptor   1   (VEGFR1)   is  
also  called  fms-­like  tyrosine  kinase  (flt-­1),  VEGFR2  is  also  known  as  fetal  liver  kinase  in  
the   mouse,   or   Kinase   Domain   containing   receptor   (KDR)   in   the   human,   and   VEGF  
receptor   3   (VEGFR3)   is   also   known   as   flt-­4.   There   are   two   neuropilin   molecules,  
neuropilin  1  and  neuropilin  2,  which  can  bind  both  VEGF  and  the  semaphorin  family  of  
proteins.  Whilst  VEGFRs  have  extensive  signalling  domains,  and  tyrosine  kinase  activity,  
the  neuropilins  have  very  short  intracellular  domains,  which  are  able  to  recruit  signalling  
molecules,  but  their  ability  to  signal  is  less  well  described.  They  do  however,  play  critical  
roles   in  VEGF  signalling  through  their  ability   to  control   the  activity  of   the  VEGFRs,  and  
are  thus  often  referred  to  as  co-­receptors.  (Figure  1).    
VEGF  splicing  
All   five  VEGFs  and  the  VEGFRs  are  generated  as  alternative  splice  variants.  VEGF-­A,  
also  known  as  Vascular  Permeability  Factor  (VPF)  or  Vasculotropin,  is  generated  from  8  
exons,   the   first   four  of  which  are  constitutively  spliced,  and  exon  8   is  used   in  all  splice  
isoforms.   Exons   5,   6   and   7   are   both   cassette   exons,   and   exons   6   and   7   can   use  
alternate  5’  splice  sites  to  generate  further  isoforms.  This  results  in  formation  of  proteins  
of  varying   length  as  all   these  are  coding  exons   (figure  2).  Exon  8  has  two  different  3’  
splice   sites,  which   leads   to   formation  of   two  different   families   of   the  VEGF-­A   isoform.  
Use   of   the  proximal   splice   site   leads   to   the  VEGF-­Axxx   family,   where   xxx  denotes   the  
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number  of  amino  acids,  and  use  of  a  distal  3’  splice  site,  66  bases  downstream  results  in  
the   VEGF-­Axxxb   family   of   isoforms.   Exon   8   contains   the   stop   codon,   which   is   just  
19nucleotides   downstream   of   the   splice   site,   so   the   VEGF-­Axxx   isoforms   have   a  
translational   stop   before   the   distal   splice   site.   There   is   also   a   stop   codon   19nt  
downstream   of   the  distal   stop   codon   resulting   in   a  mature  mRNA  with   the   same   size  
open  reading  frame  as  the  VEGF-­Axxx  isoforms,  and  hence  proteins  of  the  same  size.  So  
VEGF-­A165  has  a  sister  isoform,  VEGF-­A165b.  It  has  also  been  demonstrated  that  under  
some   circumstances   the   cell   can   choose   to   ignore   the   first   stop   codon,   in   a   process  
known  as  post-­translational   readthrough.  As   the  distal   splice   site   is  66  bases   from   the  
proximal   splice   site,   this   results   in   use   of   the   distal   stop   codon,   and   production   of   a  
protein  that  is  22  amino  acids  longer,  or  an  extended  VEGF-­A,  known  as  VEGF-­Ax.    
   All   the  VEGF-­A  splice   variants   can  bind   to  and  activate   the  VEGFRs  VEGFR1  
and  VEGFR3.  The  VEGF-­Axxx  variants  all  induce  cross  phosphorylation  of  the  7  tyrosine  
residues   in   the  c  terminal   tail.  However   their  ability   to   induce  angiogenesis   is  variable,  
due  to   their  different  heparin  binding  ability.  Exons  6  and  7  encode  for  heparin  binding  
domains,   and   heparan   sulfate   acts   as   a   facilitator   for   VEGFR2   activation   (112).   This  
means   that   VEGF-­A165   more   strongly   induces   VEGFR2   phosphorylation   that   VEGF-­
A121a.   The   latter   is   also   more   freely   diffusible,   and   secretion   of   the   different   splice  
variants  allows  a  gradient  of  angiogenic  proteins  to  be  generated  guiding  cells  to  regions  
where  vessel  growth  is  needed  (228).  In  contrast  the  VEGF-­Axxxb    family,  and  the  VEGF-­
Ax  isoform,  do  not  fully  activate  VEGFR2  and  act  as  partial  agonists,  being  able  to  only  
weakly  and  transiently  activate  phosphorylation  of  the  tyrosine  at  amino  acid  1175  f  the  
receptor   (Y1175)   but   not   Y1054.   This   means   that   VEGF-­Axxxb   cannot   stimulate  
proliferation,  or  branching  of  endothelial  cells  (136),  or  angiogenesis  (293)  (42),  but  still  
has   the   capability   to   prevent   endothelial   cell   death   (114).   The  mechanism   behind   this  
appears  to  be  dependent  on  neuropilin  binding,  as  VEGF-­Axxxb  does  not  bind  neuropilin,  
which   is  required  for  recycling  of  the  VEGFR2  to  the  surface  instead  of  degradation  by  
the  endosome   (17).  Thus  VEGF-­A165b  acts  as  a   competitive   inhibitor  of  VEGF-­A165   for  
angiogenesis,   resulting   in   it   having   anti-­angiogenic   activity   in   circumstances   where  
angiogenesis  is  VEGF-­A165  dependent  (104).  
VEGF-­B,   formed   from  7  exons  and  has   two  splice   variants,   due   to  alternate  3’  
splice  acceptor   site   in  exon  6.  The  shorter   isoform,  VEGF-­B167   is   formed  because   this  
results  in  the  stop  codon  in  exon  6  being  out  of  frame,  and  use  of  a  stop  codon  early  in  
        6  
exon  7,  and  the  additional  protein  sequence  confers  heparin  binding  affinity.  VEGF-­B186  
lacks  the  heparin  binding  domain.    
VEGF-­C   is   generated   from   8   exons,   and   exon   5   can   be   alternatively   spliced.  
However,   the   function   and   expression   of   only   the   full   length   isoform   has   been  
investigated  in  any  detail.    
VEGF-­D,  also  known  as  c-­fos   induced  growth  factor  (FIGF)   is  generated  from  7  
exons  as  two  splice  variants,  of  which  only  one  has  been  investigated  in  any  detail.    
PlGF  is  formed  from  7  exons.  This  results  in  3  known  isoforms,  PlGF1  (PlGF131)  PlGF2  
(PlGF152)   and   PlGF3   (PlGF203).   In   PlGF131,   exon   6   is   alternatively   spliced   out,   and   in  
PlGF203,  retention  of  intron  4  results  in  a  216  base  insert,  but  this  appears  to  happen  in  
the  absence  of  exon  6.    
  
VEGF  gene  transcription  
The   VEGF-­A   gene   is   activated   by   a   great   number   of   transcription   factors   and   is   the  
convergent  point   for  multiple  diverse  signalling  pathways,  which   is   reflective  of  diverse  
functions  of  VEGF.  The  vast  majority  of  studies  have  focused  on  the  role  of  hypoxia   in  
VEGF-­A  control,  as  it  is  this  hypoxia  that  is  often  thought  to  drive  VEGF-­A  expression  in  
disease  states,  and   in   remodeling   (such  as   in  exercise).  The  critical   role  of  hypoxia   in  
priming   the   transcriptional   machinery   necessary   for   massive   upregulation   of   VEGF-­A  
cannot  be  underestimated,  and  there  are  extensive  reviews  on  the  regulation  of  VEGF-­A  
by   hypoxia   (e.g.   (243)).   However,   in   normal   physiological   tissues,   VEGF-­A   is   often  
widely  expressed,   and   is   regulated.  This   is   likely  due  not   solely   to  hypoxia  but  also   to  
other   conditions.   While   hypoxia   depends   to   a   great   extent   on   the   induction   of   the  
Hypoxia   Inducing   Factor   (HIF)   complex   acting   on   hypoxia   response   elements   in   the  
VEGF-­A  promoter,  alternative  mechanisms  of  regulation  are  also  apparent.    
HIF-­Independent  transcriptional  regulation  of  VEGF.  
Deletion   of   the   HRE   (Hypoxia   response   element)   from   the   VEGF-­A   promoter   was  
sufficient   to   reduce   basal   VEGF-­A   mRNA   by   40%   in   neural   tissue,   it   remained  
unchanged   in   several   others   including   cardiac,   muscle   and   fibroblast   cells.   Under  
hypoxic   conditions   the  difference  between  normal   and  HRE  deletion  was  ~  75%(210).  
Consequently   this   provides   significant   evidence   that   there   is   also   HIF-­independent  
regulation  of  VEGF-­A,  which  at   least   is  true  for  neuronal  tissue  and  might  contribute  to  
disease   conditions   such   as   motoneurone   disease   (210).   Of   note,   subsequent   work  
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demonstrated  HIF-­independent  VEGF-­A  regulation,  even  in  cardiac  and  skeletal  tissue.  
Hypoxia   and   low   glucose   milieu,   in   peripheral   ischaemia,   increased   expression   of  
peroxisome-­proliferator-­activated   receptor-­g   coactivator   1a   (PGC-­1a)   which   in   turn  
increased  expression  of  oestrogen-­related  receptor-­a  (ERR-­a).  ERR-­a  directly  binds  to  
and  activates   the  VEGF-­A  promoter   (including  the   first   intron  sequence)  and   increases  
VEGF-­A  transcription(7).  Hypoglycaemia,  via  protein  kinase  C  (PKC)(212)  and  AP-­1  and  
activation  of  C-­Jun  and  JunB(266)  also  drives  VEGF-­A  transcription.  
VEGF-­A  promoter  activity  is  also  attenuated  by  several  transcription  factors.  The  proline-­
rich   homeodomain   protein   PRH/Hhex  binds   to   several   sites   in   the  VEGF-­A  and   other  
promoters  where   it   can   repress   several  VEGFR  genes   ,  and  also  VEGF-­A   itself   (199,  
200).  Furthermore  the  transcription  factor  SP1  binds  to  the  E3  ligase  Von  Hippel  Lindau  
(pVHL)  which  represses  VEGF-­A  transcription(185)  whereas  normally  SP1  activation   is  
required   for  VEGF-­A   transcription.  Several  other  well  known  tumour  suppressor  genes  
have   been   demonstrated   to   block   VEGF-­A   transcription,   including   p53(301)   and  
SMAD4(240).    
Shear  stress  
The   flow   of   blood   through   vessels   is   detected   by   endothelial   cells   by   the   sensing   of  
shear  stress  -­    the  physical  force  applied  to  a  surface  by  a  flowing  viscous  liquid  such  as  
plasma.   This   is   therefore   a   key   mechanism   through   which   cells   can   sense   their  
environment   and   maintain   homeostasis.   It   has   been   increasingly   recognised   that  
increasing   shear   stress   across   the  multiple   cell   types   (including   the  endothelium)   is   a  
significant   driving   force   for   multiple   genes,   including   VEGF-­A   (94,   158,   213,   268).   In  
silico  work  suggested  the  presence  of  shear-­stress  response  elements  that  are  present  
in   the   promoters   of   many   genes,   including   VEGF-­A   itself,   and   which   appear   to   be  
present   in   several   other   signalling   pathways  which   in   turn   regulate  VEGF-­A   indirectly.  
Increased  shear  stress  in  the  vasculature  drives  endothelial  nitric  oxide  synthase  (eNOS)  
upregulation(23,   38,   192,   247)   and  VEGF-­A  dependent  angiogenesis   (290,   291).   Two  
processes  that  are  intricately  linked(23).    
The   Krüppel-­like   factor   (KLF)   family   has   been   widely   implicated   in   shear   stress  
responses  with  KLF2  contributing  to  the  regulation  of  shear  stress  regulated  expression  
of   several   key   angiogenic   regulators,   including   VEGF-­A   (11).   KLF2   activation   is   an  
essential   component   in   regulating   shear   stress   induced  VEGF-­A   transcription,   its   own  
expression  is  enhanced  by  shear  stress(61),  and  KLF2-­knockdown  is  sufficient  to  reduce  
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VEGF-­A   expression,   and   augmented   KLF2   expression   further   enhances   VEGF-­A  
production  following  increased  shear  stress  (61).  
Post-­transcriptional  factors  that  influence  VEGF  expression  
The  activity  of  VEGF-­A  is  also  dependent  on  its  post-­transcriptional  processing.  VEGF-­A  
is   generated   as   contrasting   isoform   families   by   alternative   splicing   and   translational  
repression.   While   some   of   the   molecular   mechanisms   underlying   this   splicing   control  
have  begun   to  be   identified   (e.g.   the  splicing   factor  SRSF6   (198)  appears   to   stimulate  
VEGF-­A165b   expression   whereas   SRSF1   (197)   and   SRSF2   (179)   regulate   proximal  
splicing  to  generate  VEGF-­A165,  and  this  process  appears  to  be  controlled  by  activation  
of   the  splicing  factor  kinases  SRPK1  (6)  and  Clk  (171))   there   is  very   little  known  about  
what  controls  this  process  in  healthy  physiology  (e.g.  in  the  kidney,  in  ovarian  tissue  or  in  
the  pituitary  for  instance).  
The   production   of   multiple   mRNA   transcripts,   and   environmental   factor-­dependent  
mRNA   stability   (hypoxia   etc)   is   well   described.   However,   the   multi-­layered   post-­
transcriptional   control   of   VEGF   expression   also   extends   to   the   translation   of   VEGF  
mRNA   transcripts:   from   controlled   mRNA   binding   protein-­   nuclear   export   and   active  
polysome   loading   to   a   3’   UTR   riboswitch.   In   most   eukaryotic   genes   splice-­isoform  
specific   translation   is   proposed   to   be   dependent   on   non-­coding   region   interactions  
between  the  transcript   itself  and  RNA-­binding  proteins,  although  RNA-­RNA  interactions  
also   play   a   role   in   VEGF-­A   expression.   Multiple   miRNA   target   sites   have   now   been  
identified  in  in  the  human  VEGF  3’UTR  as  has  a  riboswitch  sequence  which  is  proposed  
to  influence  translation  by  a  change  in  conformation  folding  of  the  mRNA  molecule.  (8)  
Homeostatic  control  of  fluid  balance  
VEGF   and   its   receptors   are   found   to   be   expressed   in   areas   of   the   body   where   fluid  
balance   is  critically   regulated  –  both   locally,  such  as   in   the  choroid  plexus  of   the  brain  
(31,  36),  the  choriocapillaris  in  the  eye,  or  synovium  (79);;  and  systemically,  for  instance  
in  the  kidney(31),  in  resistance  vessels  and  in  the  gut(35).  There  therefore  appears  to  be  
a  role  for  VEGF  in  physiological  maintenance  of  fluid  homeostasis.  Here  we  describe  two  
different  systems  where  this  is  exemplified  –  the  kidney  and  the  eye.  
Physiological  role  of  vascular  endothelial  growth  factors  in  the  kidney  
The  glomerulus  is  a  VEGF  rich  environment  where  different  members  of  the  same  family  
can   balance   their   activities   helping   to   achieve   glomerular   function   homeostasis.   All  
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members   of   the   family   described   above   appear   to   have   active   roles   in   modifying   or  
maintaining  glomerular  filtration  barrier  ultrastructures  (fenestrations,  glycocalyx  and  the  
sub-­podocyte  space)  which  appear  to  affect  both  small  and  large  solute  permeability.  In  
disease  there  is  imbalance  in  activity  of  these  growth  factors,  but  as  we  achieve  greater  
understanding   of   the   mechanisms   behind   these   changes   to   the   glomerular   filtration  
barrier   ultrastructure   we   can  make   significant   clinical   progress   in   restoring   glomerular  
homeostasis.  
VEGFs   are   highly   expressed   in   the   kidney   glomeruli   –   the   region   of   the   renal   cortex  
where  fluid  is  filtered  across  the  glomerular  filtration  barrier  (GFB).  VEGFs  are  produced  
by  podocytes  and  play  an  important  role  in  the  development,  maintenance  and  function  
of   this   highly   specialised   filtration   barrier.   This   section   will   explore   how   these   growth  
factors  promote  cross-­talk  within  the  glomerular  filtration  barrier  and  what  the  functional  
consequences  of  these  are  in  health  and  disease.  
Podocyte  production  and  endothelial  cross  talk  
The   glomerular   filtration   barrier:   The   kidney   filters   blood   to   remove   water   and   waste  
products   whilst   retaining   essential   larger   proteins.   In   the   human   kidney   there   are  
approximately  1  million  filtering  units  (nephrons),  at  the  head  of  which  are  tangled  balls  
of  capillaries,  called  glomeruli,  where  the  blood  filtering  occurs.  The  glomerular  filtration  
barrier  is  highly  specialised  to  allow  copious  volumes  of  water  and  small  solutes  to  pass  
through  unhindered  yet  retain  the  larger  or  more  highly  charged  proteins.  The  glomerular  
endothelial   cells   (GEnC)   form   the   capillaries   and   are   highly   fenestrated.   These  
fenestrations  are  vital   to  allow  up  to  180L  of  fluid  to  flow  across   in  an  adult  kidney  in  1  
day,  and  are  dependent  upon  the  balance  of  VEGF-­A  isoforms(73,  208).  Recently  it  was  
demonstrated   that   these   fenestrations  are   not   just   empty  holes   that   allow   free   flow  of  
large   proteins,   but   are   plugged   with   a   protective   proteoglycan   layer,   the   endothelial  
glycocalyx  (e-­GLX)  (108)  (figure  3).  This  not  only  plugs  the  fenestrations  but  also  coats  
the   endothelial   cells   of   the   glomeruli   and   all   other   vascular   endothelial   cells.   The  
glomerular  endothelial  cells  are  supported  by  the  glomerular  basement  membrane  which  
is  secreted  by  both  podocytes  and  endothelial  cells,  is  unusually  thick  and  composed  of  
laminin-­521   (α5β2γ1),   collagen   α3α4α5   (IV),   nidogens-­1   and   -­2,   and   the   heparin  
sulphate   proteoglycan,   agrin   (181).   This   layer   also   allows   fluid   to   pass   relatively  
unhindered   but   the   complex   structure   and   charged   glycosaminoglycans   (GAG)    
(chondroitin   sulfate   (285)   as  well   as   heparin   sulfate)  within   it   also  help   to   restrict   and  
        10  
repel   larger   proteins.   Finally   the   glomerular   basement   membrane   is   surrounded   by  
specialised   epithelial   cells   called   podocytes.   Podocyte   cells   bodies   protrude   primary,  
secondary  and  tertiary   foot  processes  that  extend   towards  each  other  and   interdigitate  
via   a   zipper-­like   structure.   This   zipper-­like   slit   diaphragm   is   made   from   a   number   of  
proteins,  many   of  which  are   specific   to  podocytes   such   as   nephrin  and  NEPH-­1   (10).  
Beyond  the  slit  diaphragms,  primary  filtrate  does  not  simply  pass  into  Bowman’s  space  ,  
but  instead  passes  through  a  labyrinth  of  cave-­like  structures  that  underlie  the  main  body  
of  the  podocyte,  called  the  subpodocyte  space  (SPS)  (193).  The  SPSs  have  very  narrow  
openings  for  a  relatively  large  area  and  therefore  this  space  is  very  restricted.  Perfusion  
and   3D   reconstruction   studies   demonstrated   that   this   space   became   even   more  
restricted  under  physiological  perfusion  pressures  (194).  Labelled  dextrans  of  moderate  
size   (10KDa)   were   trapped   in   the   SPS,   but   not   small   molecular   weight   molecules  
(450Da)   suggesting   that   the  SPS   can   restrict   solute  movement  after   passage   through  
the  slit  diaphragm  (232).  It  is  well  established  that  each  layer  plays  an  important  role  in  
protein   filtration  and  breakdown  of  any   layer   in   isolation  can   result   in  protein   leak,  and  
that  all  the  layers  are  dependent  upon  VEGFs.  
Glomerular   VEGF-­A:   VEGF-­A   is   highly   expressed   by   human   podocytes   in   situ   in   the  
developed,  healthy  adult  kidney  (15).  The  main  role  VEGF-­A  has  been  considered  to  be    
angiogenesis,  yet   there   is  no  angiogenesis   in  healthy,  adult  glomeruli.  Thus   the   role  of  
VEGF-­A  in  the  healthy  glomerulus  is  more  complex.  In  human  podocytes  VEGF-­A  plays  
an   autocrine   role   in   podocyte   survival   (84)   through   its   interaction   with   nephrin   (85).  
Whether  VEGFR-­1  plays  an  important  role  in  VEGF-­A  signalling  is  yet  to  be  defined  (84),  
however  an  autocrine   loop   for  VEGF-­A   in  podocytes  has  been  shown   to  have  clinical  
importance  since  antibodies  that  detected  VEGF-­A  bound  to  its  receptor  (VEGFR-­1  and  
2)   are   increased   in  podocytes  during   the  progression  of   glomerulonephritis   (109).  The  
importance   of   VEGF-­A   in   glomerular   endothelial   maintenance   (74,   75)   has   been  
demonstrated   using   podocyte   specific   and   inducible   VEGF-­A   knockout   and   over-­
expressing  mice.  VEGF-­A  is  vital  for  glomerular  filtration  barrier  maintenance  in  a  highly  
dose   sensitive   manner.   The   complexity   of   the   role   of   VEGF-­A   in   diabetes   was  
highlighted  by  a  study  from  Dr  Susan  Quaggin’s  group  whereby  VEGF-­A  knock  down  in  
an   early   experimental   model   of   diabetes   was   disastrous   for   glomerular   injury.   Even  
though  elevated  VEGF-­A  levels  are  associated  with  albuminuria  in  diabetes,  VEGF-­A  is  
still   necessary   for   glomerular   function.   Therefore   a   sledgehammer   approach   of  VEGF  
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manipulation   to   aid   glomerular   repair   is   unlikely   to   be   effective,   rather   a   more   subtle  
approach  that  is  still  able  to  manage  glomerular  function  and  cyto-­protection,  is  needed.  
Glomerular   VEGF-­A165b:   With   the   discovery   of   the   anti-­angiogenic   sister   isoforms   of  
VEGF-­A  came  physiological  investigations  within  the  kidney.  VEGF-­A165b  was  originally  
discovered  when  exploring  human  renal  samples  from  healthy   individuals  or  those  with  
renal   carcinomas   (21).   It   was   revealed   that   VEGF-­A165b   was   highly   expressed   by  
podocytes   in   the  normal   tissue,   and   in   vitro   studies   in   human   podocytes   pointed   to   a  
splicing   switch   of   VEGF-­Axxx   to   VEGF-­Axxxb   isoforms   from   a   “developing”   to   a  
“differentiated”  phenotype  (51).  VEGF-­Axxxb    expression  in  the  developing  human  kidney  
was   confirmed,   and   by   adulthood   VEGF-­A165b   expression   in   the   kidney   cortex   was  
approximately   equal   to   total   VEGF-­A   (28).   VEGF-­A165b   was   shown   to   competitively  
inhibit   the   actions   of   VEGF-­A   at   VEGFR-­2   (293).   Interestingly,   in   Denys   Drash  
syndrome,  which   is   characterised  by  mutations   in   the  gene  WT-­1,   inducing  glomerular  
endothelial   cell   damage,   it   seems   that   glomerular   maturation   is   delayed.   Podocyte  
profiles  from  these  glomeruli  resemble  those  of  foetal  profiles  and  predominantly  express  
VEGF-­Axxx   isoforms,   suggesting   defective   VEGF-­A   splicing   (239).   VEGF-­A165b  
expression   at   maturation   in   glomeruli   is   a   feasible   explanation   for   why   high   levels   of  
glomerular   VEGF-­A   expression   do   not   induce   angiogenesis.   VEGF-­A165b   was   able   to  
protect  against   significant  proteinuria   in  diabetic  nephropathy,   even   in   the  presence  of  
the  additional  insult  of  overexpressed  VEGF-­A165a.  VEGF-­A165b  was  also  able  to  protect  
against   a   reduction   in   glomerular   e-­GLX   depth,   although   it   had  no  effect   on   fenestral  
density,   probably   because   this   was   already   significantly   reduced   in   diabetes.   VEGF-­
A165b  was  also  shown   to   restore  e-­GLX  ex  vivo   in   isolated  diabetic   rat  glomeruli  within  
1hr  (208).  
Glomerular  VEGF-­C:  Vascular  endothelial  growth  factor  C  (VEGF-­C)   is  also  expressed  
by  podocytes  in  human  tissue  in  situ  (131).  VEGF-­C  is  a  lymphangiogenic  growth  factor,  
and  yet  there  is  no  lymphangiogenesis  within  the  glomeruli.  This  led  to  a  similar  question  
as  podocyte  VEGF-­A  expression   -­  what   is   the  purpose  of  VEGF-­C   in   the  glomerulus?  
VEGF-­C  acts  on   vascular   endothelial   cells   as  well   as   lymphatic   endothelial   cells   and,  
intriguingly   GEnC   express   VEGFR3   as   well   as   VEGFR2   (86),   some   of   the   few  
endothelial   cells   that   express   both   (all   that   do   are   fenestrated)   (262).   Human   tissue  
culture   studies   demonstrated   that   VEGF-­C   acts   on   GEnC   to   restrict   protein   passage  
across   monolayers   (86).   Interestingly   VEGF-­C   did   not   phosphorylate   VEGFR3,   yet  
phosphorylated  VEGFR2  over  a  longer  timeframe.  VEGF-­C  also  induced  an  increase  in  
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intracellular  calcium,  but  to  a  much  lesser  extent  that  VEGF-­A.  These  data  suggest  that  
VEGF-­C   and   VEGF-­A   act   though   the   same   receptor   but   with   differing   end   points.  
Unexpectedly   VEGF-­C   reduced   the   passage   of   labelled   albumin   through   GEnC  
monolayers.  Previously  VEGF-­C  was  shown  to  cause  a  rapid  and  sustained  increase  in  
hydraulic   conductivity   in   frog   mesenteric   vessels   (106)   and   overexpression   caused  
increased  blood  vessel  leakiness  in  the  ear  (229).  VEGF-­C  was  also  shown  to  increase  
fenestration   formation   in   blood   vessels   during   neoangiogenesis   and   to   increase  
macromolecular   permeability,  although  not   to   the   same  extent   as  VEGF-­A   (40).  Thus,  
the   ability   of   VEGF-­C   to   reduce   endothelial   cell   leakiness   appears   to   be   specific   to  
GEnC,  at  least   in  vitro.  In  isolated  glomeruli  we  have  shown  that  exogenous  stimulation  
with   VEGF-­C   for   1   hr   had   no   effect   on   glomerular   albumin   permeability.   VEGF-­A  
increased  glomerular  albumin  permeability  as  expected  yet  this  effect  was  abolished  in  
the  presence  of  VEGF-­C  (209).  In  GEnC   in  vitro  VEGF-­C  promoted  survival  in  a  similar  
manner   to   VEGF-­A.  Using   transgenic   technology,   VEGF-­C  was   expressed   specifically  
by  podocytes   in  adult  mice.  Over  a  period  of  3  weeks  this  had  no  effect  on  glomerular  
function   and   GEnC   fenestration   density   remained   the   same   (209).   This   is   especially  
important   when   put   into   context   with   the   actions   of   VEGF-­A;;   podocyte-­induced  
overexpression  of  VEGF-­A  led  to  a  collapsing  glomerulopathy  and  proteinuria  (75,  282,  
283).   Interestingly   in  GEnC  VEGF-­C  was  shown  to   induce  de  novo  synthesis  of  e-­GLX  
components  whereas  VEGF-­A165  was  shown  to  induce  e-­GLX  shedding  (83).  Therefore  
VEGF-­C  appears  to  be  able  to  maintain  glomerular  function  and  override  the  detrimental  
effects   of   VEGF-­A.   This   may   play   an   important   role   in   physiology   and   has   important  
clinical  implications.    
It  is  interesting  to  note  that  two  members  of  the  same  family,  VEGF-­A165b  and  VEGF-­C,  
can   override   the  effects  of   VEGF-­A165   in   glomerular   function   and  both   are  associated  
with  e-­GLX  restoration.  Perhaps  this   is  the  key,  not  only  to  combating  the  development  
of  albuminuria  in  diabetes,  but  also  for  targeted  therapeutics  in  glomerular  pathologies.    
Fenestral  structure  and  function  
During   the   capillary   loop   stage   of   development   of   the   glomerulus,   the   GEnC   become  
flattened   against   the   glomerular   basement   membrane   and   it   is   at   this   point   that  
fenestrations  form  (16,  234).  As  stated  above,  GEnC  are  highly  fenestrated  with  regular  
pores   of   approximately   60-­70nm   diameter,   which   constitute   30-­50%   of   the   total   cell  
surface   area   (16).   Mathematical   modelling   suggests   that   the   GEnC   apply   much   less  
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resistance  to  fluid  flow  across  the  vessel  wall  than  the  glomerular  basement  membrane  
or   podocytes   (65).   These   fenestrae   are   plugged   with   e-­GLX   (52)   and   therefore   the  
fenestrae  aid  the  flow  of  very  large  volumes  of  water  and  small  solutes  but  restrict  larger  
protein  passage  due   to   size  and  charge   (201).  Unusually   for  endothelial   fenestrations,  
these  are  not   supported  by   the   structural   protein  PV-­1,  which  appears   to  be   lost  after  
development,  although  may  make  a  reappearance  during  progression  of  disease  (121).  
Fenestrae  are   formed  and  maintained   by  VEGF-­A,  an   important   part   of   the   cross   talk  
communication   between   podocytes   and   endothelial   cells.   VEGF-­A   signals   through  
VEGFR-­2  to  activate  Rho/Rac  and  induce  actin  cytoskeletal  rearrangement.  This  recruits  
PV-­1   to   the   site  of   fenestration   formation  but   this   is   subsequently   removed   (234).  The  
role  of  VEGF-­A  in  glomerular  fenestration  maintenance  was  highlighted  by  side  effects  of  
anti-­VEGF-­A  antibodies   in  the   treatment  of  cancer.  Renal  biopsies  from   these  patients  
demonstrated   thrombotic   microangiopathies   and   a   loss   of   GEnC   fenestrations,  
associated  with  proteinuria  (73).  Even  intravitreal  injections  of  MaB  VEGF-­A  were  shown  
to   localise   to   glomeruli   in   monkeys   (271).   This   can   have   specific   effects   in   disease,  
where  renal  function   is  disturbed  due  to  alterations   in  VEGF  signalling.  For   instance,   in  
patients  with  pre-­eclampsia,   characterised  by  proteinuria  associated  with  GEnC   injury,  
including   loss   of   fenestrations,   by   week   20   gestation   (24)   raised   circulating   soluble  
VEGFR1  can  inhibit  VEGF  signalling.  This  phenotype  was  recapitulated  using  transgenic  
mouse  models,  whereby  knock  down  of  a  single  VEGF-­A  allele  resulted  in  loss  of  GEnC  
fenestrations  (75).  In  addition,  in  experimental  studies  where  a  bolus  of  either  MaB  anti-­
VEGF-­A  or  sVEGFR1  were  given  to  mice,  proteinuria  developed  associated  with  GEnC  
hypertrophy  and   loss  of   fenestrations   (258).   In   renal   biopsies   from   patients  with   early  
diabetic   nephropathy   there   was   an   increase   in   GEnC   fenestration   density,   correlated  
with   increased  glomerular   filtration   rate   (GFR).   In   later   stages  of   disease   fenestrations  
were   lost   and  GFR  was   reduced   (87).   Interestingly,   loss  of   fenestrations  was  not  only  
correlated  with   reduction   in  GFR,  but   also  with   increased   albuminuria   (288).   This  eas  
attributed   to   the   loss   of   e-­GLX   that   plugs   the   fenestrations   and   coats   the   endothelial  
cells.  VEGFs  can  manipulate  both  small  and   large  solute  permeability   in  glomeruli  and  
this  suggests  that  they  can  manipulate  both  GEnC  fenestrations  and  its  e-­GLX.  
Sieving  coefficients  and  hydraulic  conductivity  
Glomerular   function   can  be  measured   in   terms  of   small   and   large   solute  permeability.  
GFR   is   a  measure  of   small   solute  permeability   of   all   functioning   nephrons  across   two  
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kidneys   and   can   be   estimated   by   creatinine   clearance   or   directly   measured   using  
labelled  inulin.  However  knowledge  of  single  nephron  GFR  is  also  helpful  since  filtration  
rates  can  vary  across  the  kidney  whilst  measurements  at  the  single  nephron  level  can  be  
controlled.   Similarly,   large   solute   (macromolecular)   permeability   can   be   measured   by  
urine   albumin:creatinine   ratios   (uACR),   yet   this   is   not   a   direct   measurement   of  
glomerular   function.   Haemodynamic   forces,   blood   flow   and   tubular   reabsorption   of  
proteins   can  all   have  an   impact.  By  measuring  glomerular   sieving   coefficients  directly,  
these  confounding  factors  can  be  bypassed.  
Glomerular   ultrafiltration   coefficients:   Glomerular   ultrafiltration   coefficient   (LpA)   is   a  
measure  of  hydraulic  conductivity  across  a  single  glomerulus.  The  effect  of  VEGF-­A  on  
rat   glomerular   ultrafiltration   coefficient  was   first  demonstrated  by  Salmon  et  al   in   2006  
(231)   using   a   modified   assay   originally   described   by   Savin   et   al   (235).   VEGF-­A   was  
shown   to   significantly   increase  glomerular   LpA/Vi   (where  Vi   is   the   initial   volume  of   the  
glomerulus).  In  contrast  when  VEGF-­A165b  was  overexpressed  specifically  in  podocytes  
it   resulted   in  a   reduction   in  LpA/Vi   in  both  homozygous  and  heterozygous  mice  which  
was   associated   with   reduced   fenestration   density   (220).   Exogenous   stimulation   of  
isolated   glomeruli   with   VEGF-­A165b   led   to   a   dose   dependent   decrease   in   LpA/Vi.  
Interestingly,   when   glomeruli   were   isolated   from   heterozygous   VEGF-­A165b  
overexpressing  mice  and  stimulated  with  VEGF-­A165,  LpA/Vi  returned  to  baseline  (220).  
Additional   transgenic   studies   proved   that   podocyte-­induced   overexpression   of   VEGF-­
A165b   blocked   the   increase   in   glomerular   LpA/Vi   in   mice   with   podocyte-­induced  
overexpression  of  VEGF-­A164  (the  mouse  pro-­angiogenic   isoform  has  164  amino  acids,  
whereas  the  human  has  165)(207).  Interestingly,  overexpression  of  podocyte  VEGF-­A164  
not  only  decreased  the  distance  between  fenestrae  but  also  induced  a  reduction  in  SPS  
coverage  of   the  glomerular   capillary  wall,  demonstrating   structural  changes   to  account  
for   reduced   restriction   to   small   solutes   and   water   (207).   Both   of   these   ultrastructural  
changes   were   ameliorated   with   VEGF-­A165b   overexpression.   That   VEGFs   can   affect  
SPS  suggests  that  they  can  modify  the  podocyte  actin  cytoskeleton  directly.    
Glomerular  sieving  coefficients:  VEGF-­A  induces  increased  uACR  (75,  282,  283).  These  
increases   in   uACR   have   been   associated   with   increased   GEnC   fenestration   density.  
Since  fenestrations  themselves  are  too  large  to  restrict  protein  passage  then  it  suggests  
the  content  of  the  fenestrations  i.e.  the  e-­GLX  must  have  changed.  Therefore  it  would  be  
anticipated   that  VEGF-­A  would   increase  GSC  due   to   loss  or   disruption  of   e-­GLX.  The  
first  study  to  show  that  VEGF-­A  modified  e-­GLX  in  GEnC  was  in  2013  (83).  This  was  an  
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in  vitro  study  on  human  cells,  that  demonstrated  the  functional  importance  of  e-­GLX  on  
these   cells   in   vitro,   as   also   shown   previously   (248),   but   demonstrated   that   VEGF-­A  
induced   shedding   of   sulphated   GAG   from   GEnC.   In   contrast   VEGF-­C   increased   the  
overall   amount   of   sulphated   GAG   that   were   synthesised   and   increased   de   novo  
synthesis   of   an   unsulphated   GAG,   hyaluronic   acid   (83).   E-­GLX   depth,   significantly  
reduced  in  Type  I  diabetic  mice  with  early  nephropathy,  is  restored  by  VEGF-­A165b  which  
also   reduced  uACR.  Therefore   it   appears   that  VEGF-­A165b  and  VEGF-­C  can  compete  
with   VEGF-­Axxx   isoforms   in   the   glomerulus   to   control   water   permeability   and   restrict  
macromolecular  protein  permeability  and  thus  both  VEGF-­A165b  and  VEGF-­C  signalling  
may  have  therapeutic  implications  in  diabetic  nephropathy  and  other  glomerulopathies.    
Physiological  role  of  VEGF-­A  in  fluid  and  solute  transport  to  and  from  the  retina.  
The  kidney  is  one  example,  but  there  are  many  tissues  in  which  fluid  flow  into  or  out  of  it  
is   both   tightly   regulated   and   not   simple.   In   the   retina,   for   instance,   two   different  
circulations,  the  retinal  and  the  choroid,  provide    retinal  blood  flow,  and  maintaining  fluid  
and  solute  transport   to  this  tissue  is  critical   for   its  function.  Retinal  pigmented  epithelial  
(RPE)  cells  form  a  monolayer  of  epithelial  cells  on  the  outer  surface  of  the  retina,  sitting  
on  Bruch’s  membrane,  and   provide   a   selectively   permeable   barrier   to   ions,   lipids   and  
fluid  between  the  outer  retina  and  the  choriocapillaris  (CC),  a  dense  area  of  fenestrated  
capillaries   in   the   choroid   (295).   Paracellular   flux   is   highly   regulated   by   tight-­junctions  
(TJs)   including   the   family   of   claudins,   occludin   and   the   zonula   occludens   (ZO)   family  
(295)  in  the  cell  membrane  that  allow  the  RPE  layer  its  barrier  function,  immune  privilege  
and  selective  transport  between  blood  and  the  neural  retina.  As  a  vital  component  of  the  
visual   cycle,   the  apical   surface  of   the  RPE  contain   villi-­like   structures   that  are   in   close  
contact  with   rod  and  cone  outer  segments   for   the  phagocytosis  of  photoreceptor  outer  
segment  discs  (255),  and  for  vitamin  A  transport  (135).    
Unlike   the   retinal   vasculature,   the   choroidal   plexus   is   fenestrated,   to   allow   both   fluid  
exchange  and  diffusion  of  nutrients  such  as  glucose  and   fatty  acids   from   the  systemic  
circulation  to  the  RPE,  which  in  turn  transports  them  to  the  outer  retina.  This  transcellular  
movement   is  also  utilised   to   transfer  outer   retinal  waste  products  back   to   the  choroidal  
circulation  (289).  The  RPE  basolaterally  secretes  VEGF-­A,  amongst  many  other  growth  
factors  and  RPE-­derived  VEGF-­A  has  an  autocrine  and  paracrine  role  on  the  RPE  and  
CC  respectively.  Conditional  VEGF-­A  deletions  result  in  a  discontinuous  RPE  monolayer  
and   an   absent   CC,   (173)   resulting   in   improper   paracellular   movement   between   the  
        16  
systemic  and   retinal   circulation.  RPE-­derived  VEGF-­A   is   involved  with  maintaining   the  
choroidal  endothelium  and  stabilising  choroidal   fenestrae  (230)  This  regulation   is  tightly  
coupled   as   the   CC   preferentially   express   VEGFR2   on   the   side   facing   the   RPE.   The  
maintenance  of  both  the  tightness  of  the  RPE  layer,  and  the  fenestrations  is  dependent  
on   expression   of   the   anti-­angiogenic   isoform   VEGF-­A165b.   RPE   cells   express   both  
VEGF-­A165  and  VEGF-­A165b  and  while  the  former  increases  the  permeability  of  RPE  cell  
layers,  the  latter  counteracts  this,  resulting  in  a  tight  junctional  barrier  which  is  disrupted  
in   diabetic   models,   and   by   hyperglycaemia(278).   VEGF-­A165b   is   also   able   to   exert   a  
protective   effect   on   both   the   RPE   cells   themselves,   where   it   acts   as   a   cytoprotective  
agent   (167)   reducing   the   effect   of   reactive   oxygen   species   and   oxidised   cholesterol.  
VEGF-­A165b   is   also   likely   to   modulate   the   effect   VEGF-­A165   from   inducing   endothelial  
proliferation  and  excess   fenestrations   in   the  CC,  as   it   does   in   the  glomerulus,   but   this  
has  yet  to  be  confirmed (278).  
  
The  RPE   also   secretes  Pigment-­Epithelial   derived   Factor   (PEDF),   an  anti-­angiogenic,  
neuroprotective  growth  factor  and  also  an  endogenous  VEGF  antagonist,  from  the  apical  
side   (1).   A   balance   between   PEDF   and   VEGF   expression   is   involved   in   CC   and   TJ  
maintenance  and  regulation,  and  therefore  fluid  and  ion  transport  across  the  outer  retinal  
barrier.  When  this  balance  is  shifted  in  favour  of  VEGF,  for  example  in  the  diabetic(2)  or  
aged   eye   (149),   there   is   increased   TJ   breakdown   in   the   RPE,   choroidal  
neovascularisation   and   aneurysm,   all   resulting   in   macromolecular   leakage   and   fluid  
accumulation  in  the  subretinal  space.  
Cytoprotection  and  metabolism  
The   crucial   roles   of   VEGF   proteins   in   the   regulation   of   microvascular   function   in  
physiology   and   pathophysiology,   has   led   to   the   use   of   VEGF-­neutralising   strategies  
becoming   an   important   therapeutic   tool   in   the   treatment   of   diseases   characterized   by  
pathological   angiogenesis   and   permeability.   However   many   VEGF   proteins   are   also  
cytoprotective   for   a   large  number  of  different   cell   types   including  endothelial,   epithelial  
and   neuronal   cells.   Systemic  anti-­VEGF-­A   therapies   can   therefore   be  associated  with  
detrimental  side  effects:  hypertension,  proteinuria,  bleeding,   inflammation  and  intestinal  
perforation,  which  can  be  fatal(45).  These  detrimental  side  effects  may  in  part  be  due  to  
the  loss  of  VEGF-­induced  cytoprotection  and  effects  on  metabolism.  
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Endothelial  cytoprotection  
All  VEGF  family  isoforms  are  ascribed  endothelial  cytoprotective  properties.  VEGF-­A  is  a  
survival   factor   for   newly   formed  vessels   in  development(92),   early   postnatal   life(5,  92)  
and  in  adulthood  (168).  It  acts  as  an  endogenous  survival  factor  for  endothelial  cells,  as  
demonstrated   by   the   effect   of   endothelial   VEGF-­A   knockout,   which   results   in   lethality  
due  to  haemorrhage  (156).  Reduced  plasma  VEGF-­A  levels  cause  vascular  attrition  and  
functional   abnormalities(258).   The   canonical   endothelial   cytoprotective   signaling  
mechanism  elicited  by  VEGF-­A   is  through  VEGFR2  activation  of  phosphatidylinositol-­3  
kinase   (PI3K)/Akt   signaling   but   the   mechanism   can   differ   depending   on   the   VEGF-­A  
splice  variant  and  vascular  bed  in  question.  For  example,  in  vitro  assays  indicate  VEGF-­
A165-­induced  human  vein  umbilical  vein  endothelial  cell  (HUVEC)  cytoprotection  depends  
upon   phosphatidylinositol-­3   kinase   (PI3K)/Akt   signaling   downstream   of   VEGFR2   and  
leads   to  upregulation  of   the  anti-­apoptotic  protein  B  cell   leukaemia/lymphoma-­2   (Bcl-­2)  
(91,  93),  whereas  VEGF-­A165b/VEGFR2-­induced  HUVEC  cytoprotection  depends  upon  
downstream   ERK1/2   signaling(167).   Differential   expression   of   VEGF   receptors  
(VEGFR1&2)   between   the   luminal   and   abluminal   endothelial   membranes,   which   is  
observed  in  pial  and  retinal  but  not  lung  endothelium,  contributes  to  the  complexity  and  
pleiotropic   nature   of   VEGF   function   including   cytoprotection.   In   plial   and   retinal  
microvessels,   Akt   phosphorylation  was   observed   following   luminal   but   not   parachymal  
application  of  VEGF-­A165   through  an  action  on  VEGFR1(116).   In  addition  PlGF   and   a  
PlGF/VEGF-­A165   heterodimer   are   both   cyto-­protective   for   microvascular   retinal  
endothelial   cells   through   VEGFR1/Akt   signalling(37,   116).   PlGF   can   also   promote  
uterine  microvascular  endothelial  survival,  along  with  VEGF-­A  and  VEGF-­C(303).  VEGF-­
B  is  a  vascular  survival  factor  for  endothelial  cells,  vascular  pericytes  and  smooth  muscle  
cells,  but  only  under  pathological  conditions.   It   is   thought   that  VEGF-­B  signals   through  
VEGFR1   and   co-­receptor   neuropilin-­1,   and   promotes   the   expression   of   cytoprotective  
factors   including   serine/threonine   kinase-­1,   VEGF-­A,   VEGF-­C   and   hypoxia-­inducible  
factor-­1a(300).  Working  through  VEGFR3,  VEGF-­C  activates  ERK1/2  and  both  VEGF-­C  
and  VEGF-­D  are  cytoprotective  through  VEGFR3  for  lymphatic  endothelial  cells(169).  In  
addition  both  VEGF-­C  and  D  bind   to  VEGFR2  and  are   cytoprotective   for   blood  vessel  
endothelia.   VEGF-­D   activates   VEGFR2   differentially   to   VEGF-­A165   yet   both   factors  
promote  HUVEC  survival  though  PI3K/Akt  signaling(127).  
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Retinal  pigmented  epithelial  cytoprotection  
The   retinal   pigmented   epithelium   (RPE),   as   well   as   providing   a   barrier   as   discussed  
earlier,   also   provides   trophic   support   to   the   photoreceptors.   The   accumulation   of  
oxidative  stress   is   thought   to  contribute   to   the  progressive  degeneration  of   the  RPE   in  
pathological   conditions   of   the   retina   such   as   age-­related   macular   degeneration  
(AMD)(292).   VEGF-­A   is   the   major   angiogenic   factor   which   promotes   ocular  
neovascularization   and   oedema(138).   There   is   evidence   that   under   normal   conditions  
the  endogenous  anti-­angiogenic  VEGF-­A  splice  variants  (VEGF-­Axxxb)  predominate  over  
the   canonical   angiogenic   splice   variants   (VEGF-­Axxx)   and   a   switch   to   favour   the  
angiogenic   variants   may   underlie   pathological   retinal   angiogenesis   (216).   In   the  
neovascular   (wet  or   exudative)   form  of  AMD,   choroidal   vessels   invade  and  disrupt   the  
retina   and   vision   of   patients   and   pan-­inhibition   of   VEGF-­A   protein   has   transformed  
therapy   of   the   disease.   However   both   VEGF-­A165   and   VEGF-­A165b   variants   are  
cytoprotective   for   RPE   cells(167)   and   inhibiting   all   VEGF-­A   splice   variants   with  
bevacizumab  or  a  neutralizing  specific  VEGF-­A165b  antibody  is  cytotoxic  (167,  254)  and  
downregulates  RPE  Bcl-­2  expression(142).  A  number  of  pre-­clinical   investigations  and  
clinical  reports  have  documented  that  intra-­vitreal  VEGF-­A  neutralization  does  not  cause  
short-­term   functional  abnormalities   (105,  122,  141,  267).  However  a  number  of   reports  
detail  signs  of  retinal  damage  (3,  12,  122,  142,  217).  For  example  following  a  single  dose  
of   intra-­vitreal   bevacizumab   in   rabbits,   the   pro-­apoptotic   proteins   b-­cell   lymphoma  
associated   x   protein   (bax),   caspase-­3   and   caspase-­9,   were   upregulated   in   the   outer  
layers   of   the   retina,   in   particular   in   the   photoreceptors,   as   detected   by  
immunohistochemistry  (122),  and  electron  microscopy  revealed  mitochondrial  damage  in  
the  inner  segment  of  the  photoreceptors  (122).  Nuclear  DNA  fragmentation  in  the  outer  
retinal   layers,  as  detected  by  the  TUNEL  method  was  evident  14  days   following  single  
injection  of  anti-­VEGF-­A  or  three  months  following  monthly   injections  (12).  Whether  the  
retinal  toxicities  from  neutralizing  VEGF-­A  arise  due  to  the  disruption  of  direct  VEGF-­A-­
mediated  cytoprotection  or  due  to  an   indirect  effect  such  as   the  disruption  of  VEGF-­A-­
mediated   vascular   perfusion   is   not   clear   to   date.   Evidence   suggests   long-­term   pan-­
VEGF-­A   neutralization   in   angiogenic   ocular   disease   will   have   a   detrimental   effect   on  
retinal  health,  whereas  a  more  selective  approach  to  neutralize  the  pathology-­associated  
splice  variants  (VEGF-­Axxx),  either  by  the  specific  antibody  or  pharmacological  inhibition  
or   by   altering   the   balance   of   VEGF-­A   splice   variants,   may   have   the   desired   anti-­
angiogenic  action  without  the  long-­term  detrimental  cytotoxicity.  
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RPE   cells   express   other   VEGF   family   isoforms,   VEGF-­B,   C,   D   and   PlGF   and   their  
respective   role   in  ocular   pathological   angiogenesis   is  under   investigation,   although   the  
possible   roles   in   RPE   cytoprotection   is   unclear   and   warrants   further   research.  
Neutralizing  VEGF-­A  will   remove   the  VEGF-­A-­mediated  positive   feedback  on  VEGF-­A  
and   VEGF   receptor   expression.   Therefore   it   is   likely   that   any   cytoprotective   action   of  
other  VEGFs  that  signal  through  VEGFR1  and  2  will  also  be  negatively  affected  by  anti-­
VEGF  therapy.  
VEGFs  as  multi-­functional  cytokines  
It  has  become  increasingly  clear  over  the   last  few  years  that  VEGF  is  a  multifunctional  
cytokine.   It   can   act   on   many   cell   types,   in   many   tissues   to   contribute   roles   that   are  
outwith  its  original  description  as  either  a  growth  factor  or  permeability  factor.  In  different  
cell   types   VEGFs   can   act   as   regulators   of   cell   death,   cell   metabolism,   cell  
communication  and  cell  plasticity.  Here  we  will  investigate  some  of  those  processes  that  
contribute   to  how   the  body   can  maintain   functions  as  diverse  as  gas  exchange   in   the  
lung,  to  learning  and  memory  and  pain  detection.  
VEGF  in  the  normal  adult  lung  
VEGFR1  and  VEGFR2  are  abundantly  expressed  within  the  vascular  bed  of  the  normal  
lung  and   are   critical   for   normal   development   (244).   They  are   also   expressed   by  non-­
endothelial  cells  (non-­ECs)  including  lung  macrophages  (236)  (50)  and  alveolar  epithelial  
type   II   (ATII)   cells   (81)   (172)   (176),   although   the   exact   role   of   VEGF   in   the   alveolar  
compartment  is  not  currently  fully  understood.    
Neuropilins  1  and  2  (NRP  1  and  NRP2)  have  been  identified  on  several  cell  types  within  
the  lung  including  adult  ECs  (249)  and  ATII  cells  (177),  although  their  role  has  not  been  
fully  defined.  Neuropilins  are  transmembrane  glycoproteins,  which  notably  have  a  short  
cytoplasmic   domain   and   as   such   are   thought   to   transduce   functional   responses   only  
when   co-­expressed   with   other   receptors   (196).   Contrasting   evidence   exists   however,  
suggesting  that  NRP1  is  able  to  support  VEGF-­induced  cellular  signalling  independent  of  
VEGFR2   (99)   and  may   have   an   independent   role   in   the  maintenance   of   normal   lung  
structure  (123).  Of  all  the  adult  organs,  VEGF-­A  mRNA  expression  is  highest  in  the  lung  
in   both   animals   and   humans   (183)   (27).   VEGF-­A   and   its   receptors/co-­receptors   are  
expressed  on  both   sides  of   the   alveolar-­capillary  membrane   (ACM)   (68).   The  alveolar  
epithelium  is  considered  to  be  the  predominant  source  of  VEGF-­A  in  the  lung  ((27,  172),  
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(132),  although  a  variety  of  cells  such  as  smooth  muscle  cells,  macrophages  and  ECs  
also  express  VEGF-­A  (294,  297)).    
Interestingly   in  health,  VEGF-­A  expression  within  the   lung  is  highly  compartmentalised.  
Alveolar  protein   levels  have  been  reported  to  be  500  times  (2nM)  that  of  plasma  levels  
(132)  and  double  that  previously  described  as  being  required  to  induce  biological  effects  
in   vivo   (67).   Yet   paradoxically,   the   classical   processes   linked   to   VEGF-­A   activity  
(permeability,  angiogenesis,  mitogenesis)  are  extremely  limited  in  the  mature  lung.  This  
suggests  an  additional  function  for  VEGF-­A  beyond  development.  It  has  been  proposed  
that  in  the  adult  lung,  VEGF-­A  may  assist  in  maintaining  a  healthy  lung,  which  crucially  
depends   upon   the   compartmentalisation   of   VEGF-­A   through   an   intact   ACM   (178).  
Supporting   this   theory,  VEGFR  and  co-­receptors  are   found  on  both   sides  of   the  ACM  
(177)  and   in  vitro  VEGF-­A  acts  as  a  survival  and  anti-­apoptotic  factor  for  both  epithelial  
(189)   (225)   (148)   and  ECs   in   the  normal   lung   (91)   (93)   (4).   Furthermore,   blockade   of  
VEGF-­A   signalling   induces  an   emphysema   phenotype   in   several   animal  models   (188)  
(134)   (263)   (272)).   The   magnitude   of   VEGF-­A   expression   also   appears   to   be   tightly  
regulated  in  the  normal  lung;;  overexpression  of  VEGF-­A  in  respiratory  cells  of  adult  mice  
also  induces  emphysematous  change  (153),  pulmonary  oedema  and  angiogenesis  (29).    
VEGF-­A  may  have  a  role   in  repair  of   the   lung  following  injury,  with  the  ability   to   induce  
proliferation   of   the   systemic   vasculature   (157),   growth   of   ATII   cells   (34)   (277)   and  
stimulate   ATII   cell   surfactant   production   (48).   Additionally,   via   its   interaction   with  
VEGFR1,   VEGF-­A   appears   to   regulate   apoptotic   cell   clearance   by   alveolar  
macrophages,   another   important   process   in   the   maintenance   of   tissue   structure   and  
function  (137).  VEGF-­B,  VEGF-­C,  VEGF-­D  and  PlGF  are  all  thought  to  contribute  to  the  
physiological   development   of   the   lung   (125,   126)   (97)   (56)).   Their   role   in  normal   lung  
maintenance   is   less   well   understood   but   over-­expression   of   PlGF   in   animal   models  
appears  to   induce  emphysematous  changes  (270).   It  has  recently  been  shown  that  the  
isoform  specific   expression   of   VEGF-­A   is   important   for   the  development   of   pulmonary  
fibrosis  both   in  vitro  and   in  pre-­clinical  murine  models.  Differential   expression  of   these  
isoforms   may   explain,   in   part,   some   of   the   apparently   conflicting   studies   describing  
VEGF-­A   as   both   a   protective   and   contributory   factor.   In   this   study   ATII   cell   derived  
VEGF-­Axxx  was   critical   for   the  development  of   fibrosis   in  a  preclinical  model  of   fibrosis  
with  an  inhibitory/regulatory  function  for  VEGF-­Axxxb  isoforms(19).    
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VEGF  and  endothelial  cell  metabolism  
Vessel   growth   in   normal   as   well   as   diseased   tissues   relies   upon   the   generation   of  
specialised  endothelial  cells  that   form  the  growing  tip  of  vessel  sprouts.  These  tip  cells  
are  followed  by  stalk  cells  –  further  specialised  cells  that  proliferate  and  repress  tip  cell  
phenotypic   alterations,   such   as   filopodia   and   lamellipodia   that   can   route-­find   and   help  
the  sprout  grow.  The  remaining  endothelial  cells  cover  the  lumen  of  blood  vessels,  but  all  
endothelial  cells  are  in  close  proximity  to  the  high  oxygen  concentrations  present  in  the  
blood.   However,   endothelial   cells   do   not   rely   on   an   oxidative   metabolism,   but   use   a  
VEGF-­A   dependent   glycolytic   pathway   for   metabolism   when   they   grow.   Vessel  
branching   is   not   affected   by   inhibition   of   mitochondrial   respiration   (54).   Instead,  
glycolysis   seems   to  be   the   predominant  bioenergetic   pathway   for   endothelial   cells,   as  
they   are   glucose-­addicted   and   generate   most   of   their   ATP   (85%)   via   glycolysis   (54).  
However,   glycolysis   with   lactate   production   yields   only   two   molecules   of   ATP   per  
molecule   of   glucose,   as   compared   to   the   36   molecules   of   ATP   generated   via   the  
oxidative  metabolism  of  glucose.    
Glycolysis  can  offer  many  benefits  to  endothelial  cells.  First  of  all,  glycolysis  generates  
ATP   faster   than   oxidative   phosphorylation,   providing   endothelial   cells   with   the   energy  
they  need   for   the   formation  of   new  blood  vessels  and   therefore  allowing  a  more   rapid  
restoration  of  the  oxygen  supply  in  the  surrounding  tissues.  Secondly,  the  mobilization  of  
glycolytic   metabolites   into   secondary   metabolic   pathways   for   the   generation   of  
macromolecules   for  biomass  synthesis  during   cell   proliferation  or   for   the  production  of  
reducing  power  for  redox  homeostasis  may  further  contribute  to  a  rapid  vascularization.  
Third,  by  favouring  glycolysis  in  the  presence  of  oxygen,  endothelial  cells  produce  lower  
amounts  of  reactive  oxygen  species.  Fourth,  this  way,  the  maximal  amounts  of  oxygen  
are  preserved  for  perivascular  cells.  Fifth,  with  an  enhanced  glycolysis,  endothelial  cells  
produce  more  lactate  independently  of  oxygen,  which  in  turn  can  act  as  a  pro-­angiogenic  
signalling  molecule   itself,   further   supporting   vessel   growth   and  branching   (107).  Sixth,  
glycolytic  enzymes  can  be  compartmentalized  with  F-­actin  and  therefore  arranged  on  a  
cellular  matrix  similar  to  an  assembly  line,  where  metabolic  substrates  are  passed  from  
one  enzyme  to  the  following  one.  Localizing  the  ATP  production  to  those  places  where  it  
is  consumed,  can  be  crucial.  For  instance,  mitochondria,  due  to  their  structure  and  size,  
do   not   fit   into  narrow   lamellipodia.  Hence,   compartmentalisation  of   glycolytic   enzymes  
facilitates  ATP  supply  in  lamellipodia  to  fuel  migration  of  tip  endothelial  cells  (55).  Finally,  
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and  most  importantly,  if  endothelial  cells  would  depend  on  oxidative  glucose  metabolism,  
the  vascularisation  of  anoxic  tissues  would  not  be  possible  (69).  
One  of   the   rate-­limiting  steps   in   the  glycolytic  pathway   is   the  conversion  of   fructose-­6-­
phosphate   (F6P)   to   fructose-­1,6-­bisphosphate   (F1,6P2),   which   is   performed   by   6-­
phosphofructo-­1-­kinase   (PFK-­1).   Phosphofructokinase-­2/fructose-­2,6-­bisphosphatase  
(PFKFB)  enzymes  synthesize  fructose-­2,6-­bisphosphate  (F2,6P2),  an  allosteric  activator  
of   PFK-­1   and   a   potent   stimulator   of   glycolysis   (275).   In   this   context,   VEGF-­A   directly  
modulates  glycolysis   via  upregulation  of   the  expression   levels  of   the  enzyme  PFKFB3  
(55),   which   is   able   to   double   the   rate   of   glycolysis.   In   addition,   genetic   and  
pharmacological  inhibition  of  PFKFB3  in  endothelial  cells  reduces  glycolysis  and  impairs  
vascular  sprouting  by  decreasing  both  the  proliferation  of  stalk  cells,  and  by  impeding  the  
formation   of   filopodia   in   tip   cells,   thus   preventing   their   migration   (55,   237).   PFKFB3  
colocalises  with  F-­actin,  as  also   reported   for  other  glycolytic  enzymes   (222).   Increased  
PFKFB3   expression   and   glycolytic   ATP   production   are   detected   in   the   lamellipodia  
compartment   of   migrating   endothelial   cells.   In   addition,   stimulation   of   glycolysis   by  
PFKFB3  overexpression   induces   the   tip  cell  phenotype  during  vessel  sprouting   in  vitro  
and  in  vivo  (55,  237).  Thus,  a  change  in  metabolism  alone,  in  particular  PFKFB3-­driven  
glycolysis,  is  sufficient  to  promote  tip  cell  behaviour  giving  raise  to  vessel  outgrowth  and  
branching.    
Once  a  newly  formed  vessel  is  established,  though,  quiescent  endothelial  cells  appear  to  
re-­program   their   glucose   metabolism   by   downregulating   glycolysis.   Non-­proliferative,  
contact-­inhibited   endothelial   cells   in   vitro,   which  mimic   the   quiescent   endothelium,  are  
less  glycolytic  than  proliferating  endothelial  cells  (237).   In  accordance,  endothelial  cells  
under   laminar   shear   stress   as   a   surrogate   of   blood   flow   lower   their   glucose   uptake,  
repress  PFKFB3  expression  and   reduce  glycolysis   (62).  Furthermore,   in   this   scenario,  
expression   and   autocrine   signalling   of   VEGF-­A   by   endothelial   cells   seems   to   be  
necessary  to  sustain  the  integrity  of  the  already  established  vascular  network.  Depletion  
of  VEGF-­A  from  the  endothelium  results   in  mitochondrial   fragmentation  and   repression  
of   mitochondrial   respiration,   oxygen   consumption,   glucose   uptake,   lactate   production  
and   triglyceride   synthesis,   resulting   in   increased   autophagy   and   cell   death   via  
upregulation  of   the  transcription  factor  FOXO1  (64).  Thus,  autocrine  VEGF-­A  signalling  
is   essential   for   the  maintenance   of   a  normal  metabolic   phenotype   in   endothelial   cells.  
How  VEGF-­A  can  stimulate  both  oxidative  metabolism  and  glycolytic  metabolism  is  not  
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known,   but   could   depend   on   the   status   of   the   VEGFR   receptor   signalling,   and   the  
isoforms  of  VEGF-­A  being  expressed.  
VEGF  regulation  of  fatty  acid  uptake.  
VEGFs  are  also  involved  in  uptake  and  transport  of  fatty  acids  across  and  into  cells.  
While  medium  (<12  carbons)  and  short  chain  (<6  carbons)  fatty  acids  can  freely  diffuse  
across  the  phospholipid  bilayer,   long  chain  fatty  acids  (LCFA)  require  the  assistance  of  
membrane  anchored  proteins  (101).  Currently,   there  are  four  proposed  mechanisms  by  
which  FA  can  pass  through  the  plasma  membrane  into  the  cytoplasm  of  cells:  1.  Simple  
diffusion;;   2.   CD36   alone   or   in   combination   with   the   extracellular   FA   binding   protein  
(FABP)  bind  onto  FA  to  increase  local  FA  concentration  to  facilitate  passive  diffusion;;  3.  
CD36  may  be  able  to  actively  transport  FA  into  the  cytoplasm;;  4.  Transportation  by  FA  
transporting   proteins   (FATP)(241).   FATPs   form   an   integral   part   of   the   LCFA   uptake  
process  and  studies   suggest   the   importance  of  VEGF-­B  signalling   in   the   regulation  of  
FATP   expression   on   the   endothelium   (102).   Overexpression   of   VEGF-­B   upregulates  
FATP3  and  4,  while  VEGF-­B  or  Flt1  knockout  downregulates  FATPs  in  the  endothelium  
of   the  heart   (102).   Indeed,   the  VEGF-­B  knockout  animals  have  a   reduced   lipid  uptake  
compared  with  the  controls,  suggesting  the  importance  of  VEGFR1  signaling  and  FATP  
in  the  transportation  of  FA  in  vivo  (102).    
VEGF-­A  mediated  activation  of  VEGFR2  upregulates  FA  binding  protein  (FABP4)  in  the  
endothelium,  which   is   involved   in   the   trafficking  and  storage  of  FA  (72,  88).  Moreover,  
promotion  of  angiogenesis  through  VEGF-­A  or  VEGFR2  has  a  protective  role  in  obesity  
by  reducing  lipid  uptake  (71,  259).  While  VEGF-­B  is  a  weak  angiogenic  factor  compared  
with   VEGF-­A,   when   VEGF-­B   is   overexpressed   in   adipose   tissues,   it   is   capable   of  
enhancing  the  microvascular  density  and  reduce  lipid  deposition.  The  apparent  VEGF-­B  
induced   angiogenesis   has   been   postulated   to   function   by   displacing   VEGF-­A   from  
VEGFR1,   allowing   it   bind   to   VEGFR2   (224).   The   precise   role   of   VEGF-­B   remains  
controversial.  While   some  studies   suggest  VEGF-­B   inhibition   reduces   lipid  uptake  and  
increases   insulin   sensitivity   in   a  mouse  model   of   diabetes   (102,   103),   others   showed  
VEGF-­B   overexpression   did   not   provide   these   benefits   (224)   but   improved   insulin  
delivery  in  the  adipose  tissue  (224)  and  plays  a  protective  role  during  cardiac  ischaemia  
(145).  VEGF-­B  upregulation  in  transgenic  mice  appeared  to  induce  cardiac  hypertrophy,  
resulting  in  lowered  blood  pressure  and  heart  rate.  However,  this  was  accompanied  with  
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altered   lipid   composition   with   excessive   FA   uptake,   elevated   ceramide   production,  
mitochondrial  damage  and  increased  fatality  of  the  transgenic  animals  (133).    
  
VEGF  in  skeletal  muscle  physiology  and  metabolism  
Skeletal   muscle   requires   a   dense   and   responsive   vasculature.   Capillaries   feeding  
skeletal   muscle   have   a   thin   endothelium,   with   cytoplasmic   vesicles   but   few   other  
organelles,   with   an   intact   basement   membrane   and   smooth   luminal   and   abluminal  
surfaces  (70).  This  structure  maximizes  the  contact  surface  area  between  capillaries  and  
myofibres,  which  facilitates  oxygen  diffusion  and  removal  of  metabolites.  Since  metabolic  
demands   in   skeletal  muscle  are  sensed  via  motor  units,   each  unit   exerts   independent  
control  of  blood  flow.  This  means  that  a  highly  hierarchical  vascular  structure  is  present  
in   skeletal   muscle.   Larger   arterioles   (up   to   the   third   order:   A3),   possess   vasomotor  
activity,  control  resistance  and  blood  flow  through  the  tissue.  The  more  distal  portion  of  
the  arteriolar   tree   (from   the  branch  arteriole:  A4,   to   the  module   inflow  arteriole:  A5)   is  
involved  in  the  regulation  of  capillary  recruitment  and  blood  flow  distribution  (191).    
Altering   metabolic   demands,   such   as   subjecting   the   highly   plastic   skeletal   muscle   to  
exercise  training,  results  in  hypoxia,  which  induces  expression  of  VEGF-­A165a  in  skeletal  
muscle  cells.  This  results  as  both  a  vasodilator  (147),  enabling  feeding  arterioles  (A3)  to  
respond  by   sustained   increase   in  blood   flow,   increased  surface  area  by  dilation  of  A4  
and  A5  arterioles  and  active  angiogenesis(273),  which  increases  surface  area  available  
for  solute  exchange  in  capillaries.  One  consequence  of  this  is  likely  to  be  the  reduction  in  
blood  flow  seen  in  exercise  when  muscle  specific  VEGF  is  not  available(146).  However  
VEGF  driven  angiogenesis  can  also  directly  affect  changes  in  skeletal  muscle  fibre  type  
composition  (287).  These  fibres  differ  in  their  function  but  also  in  mitochondrial  content,  
expression  of  VEGF  and  capillary  involvement  (111).  It  has  been  proposed  that  VEGF  is  
secreted   to   the   interstitial   space   upon   muscle   contraction   (111),   but   it   is   unclear   the  
effect  this  exerts  in  the  established  vascular  network.  
In   some   disease   states,   such   as   peripheral   arterial   disease   and   diabetes,   impaired  
VEGF  signaling  in  skeletal  muscle  correlates  with  poor  prognosis  (180)  (164)  (30).  VEGF  
has  been  identified  as  the  main  facilitator  of  angiogenesis  in  muscle,  but  the  exact  nature  
of   this   signaling   is   debatable,   as  both  pro-­   and  anti-­angiogenic   isoforms   of   VEGF   are  
generated  in  response  to  ischemia,  depending  on  the  metabolic  status  of  the  individual  –  
people  with  metabolic  dysfunction  are  more  likely  to  generate  anti-­angiogenic  isoforms  of  
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VEGF   in   response   to   ischemia,   thus   exacerbating   the   problem   and   contributing   to  
peripheral,   and  potentially   coronary,   arterial   disease(139).   It   has   recently   been   shown  
that  VEGF   is  essential   in   controlling  arterialization  and,   thus,  distribution  of   blood   flow  
through  the  tissue  (204)  (256).    
Using   targeted  deletion  of   VEGF   in   specific   cell   types,   studies   in  animal  models   have  
elucidated   the   importance  of  VEGF   signaling   in   skeletal  muscle,   both   in   exercise  and  
disease.   VEGF   of   endothelial   origin   seems   to   be   necessary   for   EC   survival   since  
VEGFECKO  mice  display  significant  endothelial  dysfunction,  even  with  levels  of  circulating  
VEGF   similar   to   their   wild-­type   littermates   (156).   VEGF   of   skeletal   muscle   origin   was  
found  to  be  essential  for  the  maintenance  of  capillary-­to-­fibre  ratio  and  capillary  density  
(205).  Capillary   rarefaction   that  occurred  as  a   result  of  depleted  muscle-­specific  VEGF  
was  also  found  to  contribute  to  augmented  fasting  glucose  turnover.  This  was  sufficient  
to  induce  muscle  insulin  resistance  in  lean  mice  (30).  A  reduction  of  over  90%  in  muscle  
VEGF  protein   severely   hindered  maximal   running   speed   and  exercise   performance   in  
mice   (205).   Olfert   and   colleagues   have   also   found   that   myocyte-­derived   VEGF   is  
essential   for  muscle  capillary  adaptation   to  exercise   training   (206).  However,  myocyte-­
derived  VEGF  is  not  the  sole  contributor  of  skeletal  muscle  adaptation  to  exercise.  Mice  
where   VEGF   has   been   knocked-­down   in   adipose   tissue   exhibit   increased   insulin  
sensitivity   and   impaired   endurance   running,   probably   due   to   blunted   transport   of   lipid  
stores  (299).  Furthermore,  after  exercise,  a  lack  of  continued  training  (detraining)  results  
in  a  reduction  of  vasculature,  but  VEGF  is  still  maintained  high.  Studies  have  suggested  
that  this  might  be  a  consequence  of  over-­expression  of  anti-­angiogenic  factors  such  as  
TSP1,  but  a  role  for  VEGF-­A165b  has  not  yet  been  considered  (203).  Detailed  studies  of  
the   differing   effects   between   autocrine   and   paracrine   VEGF   signaling   in   muscle   are  
going  to  be  necessary  to  be  able  to  fully  understand  how  VEGF  controls  both  response  
to  exercise,  and  control   of  metabolic  demand   in  both  healthy  patients  and   in   ischemic  
disease.    
Control  of  function  in  the  nervous  system    
Since  its  original  discovery  the  role  of  VEGF  in  the  nervous  system  has  been  clear,  but  
perhaps  underappreciated.  From  angiogenic  control  of  pituitary  function,  to  its  role  as  a  
regulator  of  hormonal  release,  synaptic  plasticity  and  pain  sensations,  it  is  perhaps  the  
neuronal  aspects  of  VEGF  function  that  are  most  overlooked  in  normal  physiology.  Here  
we  identify  some  of  the  key  aspects  of  VEGF  in  the  nervous  system.  
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Pituitary  function    
VEGF-­A  was  first  isolated  and  purified  by  Napoleone  Ferrara,  one  of  the  co-­discoverers  
of  VEGF,  from  pituitary  folliculostellate  cells  (FSC)  (157),  indicating  that  the  pituitary  can  
be  in  charge  of  the  regulation  of   its  own  vasculature.  FSC  are  non-­endocrine  cells  that  
form  a  three-­dimensional  network  throughout  the  pituitary  and  can  modulate  the  function  
of  endocrine  cells  in  a  paracrine  manner.  These  cells  have  been  shown  to  display  a  high  
degree   of   plasticity,   and   in   animals   that   change   their   physiology   with   season   (e.g.  
reproduction,   fur   growth,   horn   growth   etc),   FSC   demonstrate   overt   ultrastructural  
changes   and   varied   number   of   adherens   junctions   across   the   year   in   response   to  
seasonal   changes   in  photoperiod.   (46).  Moreover,   we  have   recently   shown   that   these  
changes  are  accompanied  by  a  significant  increase  in  the  density  of  FSC  within  the  pars  
distalis  of  the  pituitary  gland  during  the  long  days  of  summer  (41).  It  was  thus  surprising  
that   the   production   of   VEGF-­A   was   reported   to   remain   unchanged   under   different  
photoperiods  (124),  and  the  role  of  VEGF-­A  production  by  FSC  in  pituitary  function  has  
gone  undiscovered  for  nearly  30  years.  
In  vertebrates,  the  pituitary  gland  plays  a  key  role  in  maintaining  homeostasis  by  means  
of  a   tightly   regulated   secretion  of   hormones   that   control   a   variety  of   functions   such  as  
metabolism,  the  response  to  stress,  body  growth,  reproduction  and  lactation.  This  organ  
comprises  two  parts  of  different  embryological  origin  that  are  fused  during  development,  
a  glandular   part   referred   to  as   the  adenohypophysis  or  anterior  pituitary,  and  a  neural  
part   known  as   the  neurohypophysis,   of   which   its  major   component   is   also   sometimes  
referred   to   as   the   posterior   pituitary.   The   glandular   component   is   composed   of   three  
distinctive   regions:   the   pars   tuberalis,   the   pars   distalis   and   the   pars   intermedia.   The  
neural   component   contains   fibres   originating   in   the   hypothalamus   and   includes   the  
neural  stalk  and  the  neural  lobe,  or  pars  nervosa (96).  A  major  difference  with  regard  to  
hormone  output  between   the  glandular  and  neural  part  of   the  pituitary,   is   that  whereas  
the  former  secretes  homones  produced  locally,  the  latter  releases  hormones  produced  in  
hypothalamic  nuclei.  Because  the  local  production  of  hormones  within  the  pituitary  gland  
relies   on   stimulatory   and   inhibitory   hypothalamic   signals,   communication   between   the  
brain   and   pituitary   for   the   delivery   of   those   signals   is   of   fundamental   importance   to  
ensure  normal  control  of  pituitary  function.  In  mammals,  this  communication  is  achieved  
by  means  of   an  elegant  portal   vascular   system   that  also  ensures   inter-­communication  
among   the   different   parts   of   the   pituitary.   The   hypothalamic-­pituitary   portal   system  
originates   in  the  superior  (or  anterior,  depending  on  species)  hypophysial  artery,  which  
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will  give   rise   to  a  proximal  primary  capillary  plexus  between  the  median  eminence  and  
the  pituitary  stalk   from  where   the   long  portal  vessels  arise   (218).  These  portal  vessels  
carry   the   blood   that   flows   from   the   brain   to   the   pars   distalis   (113).   The   inferior   (or  
posterior)   hypophysial   artery   supplies   the   pars   nervosa,   and   in   some   species   also  
generates  a  more  distal   capillary  plexus  with   short   portal   vessels   that   primarily   supply  
the   region  of   the  pars  distalis   neighbouring  neural   tissue(95).  Thus,   the   vasculature  of  
the  pars   distalis   of   the  pituitary   gland   is   deprived   of   arterial   vessels   and   comprises   a  
secondary  capillary  plexus  that  is  entirely  composed  of  veins.    
Using  the  sheep  as  the  experimental  model,  a  detailed  examination  of  the  origin  of   the  
long  portal  vessels  revealed  that  branches  from  the  proximal  capillary  plexus  cross  the  
pars   tuberalis   before  penetrating   into   the   neural   component   of   the   pituitary   stalk,   and  
then  loop  to  return  to  the  pars  tuberalis  from  where  they  continue  into  the  pars  distalis  as  
long  vessels  (53).  This  glandular-­neural  intra-­pituitary  communication  is  likely  to  have  an  
important  physiological   role  because:  1)   the  pars   tuberalis   is   the   tissue   responsible   for  
annual   time   measurement;;   2)   the   neural   stalk   contains   a   high   density   of   glial-­type  
foliculostellate   cells;;   and  3)   the  pars  distalis   is   the  major   source  of   pituitary  hormones  
that   control   body   functions.   Therefore,   it   can   be   anticipated   that   regulation   of   the  
hypothalamic-­pituitary   portal   system   will   have   an   impact   on   the   multiple   systems  
controlled  by   the  pituitary   gland.   In   support   of   this   prediction,  when   the   expression  of  
specific  VEGF-­A  isoforms  was  investigated,  it  became  apparent  that  the  output  of  VEGF-­
A  subtypes  is  dramatically  affected  by  photoperiod.  Indeed,  the  pro-­angiogenic  isoforms  
of  VEGF-­A,  VEGF-­Axxx,  are  upregulated  during  the  long  days  of  summer  at  the  expense  
of  a  decrease  in  the  anti-­angiogenic  variants,  VEGF-­Axxxb  .  Conversely,  during  the  short  
days  of  winter  the  anti-­angiogenic  VEGF-­Axxxb  variant   is  upregulated  at   the  expense  of  
the   proangiogenic   VEGF-­Axxx   variant   (41).   This   seasonally   regulated   differential  
expression   of   VEGF-­A   isoforms   results   from   alternative   splicing   of   a   single   VEGF-­A  
gene,  and   leads  to  a   remarkable  alteration   in   the  pituitary  microvasculature  throughout  
the  year.  The  number  of  vascular  loops  and  the  vascular  loop  area  are  increased  during  
the  long  days  of  summer,  adding  communication  between  the  brain  and  the  pituitary  at  
this   time.  This   increase   in   the   vascular   connection  was  associated  with  an   increase   in  
endothelial   cell   proliferation.   In   contrast,   during   the   short   days   of   winter   a   significant  
reduction  in  the  number  of  vascular  loops  and  vascular  loop  area  was  associated  with  a  
decrease  in  endothelial  cell  proliferation.  Thus,  the  pituitary  microvasculature  undergoes  
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profound   remodelling  across   the   year   through  a  seasonally   regulated,  VEGF-­mediated  
mechanism.    
Seasonal  changes   in  day   length  are  encoded  by   the  duration  of  melatonin  output   from  
the  pineal  gland  during  the  night,  so  that  the  long  days  of  summer  are  associated  with  a  
short  duration  of  melatonin  secretion,  whereas  the  short  days  of  winter  are   linked   to  a  
long   duration   of   melatonin   production.   A   major   site   of   action   for   this   photoperiod  
encoding  melatonin  signal   is   the  pars  tuberalis  of   the  pituitary.  This  tissue  contains  the  
highest  density  of  melatonin  receptors  in  the  entire  body,  and  is  known  to  play  a  crucial  
role   in  mediating   the  melatonin   translation  of   photoperiodic   information   (57).  Melatonin  
receptors   in  this  region  of   the  pituitary  are  expressed  not  only   in  pars  tuberalis  specific  
cells,  but  also  in  the  vascular  loops  that  will  give  rise  to  the  long  portal  vessels  (41).  The  
duration  of  melatonin  exposure  induces  differential  expression  of  VEGF-­A  isoforms,  with  
proangiogenic   VEGF-­Axxx   isoforms   induced   by   short   duration   of   the   melatonin   signal,  
typical  of  the  long  days  of  summer,  and  antiangiogenic  VEGF-­Axxxb  isoforms  induced  by  
long  duration  of  melatonin   signal   characteristic   of   the   short   days  of  winter,   revealing  a  
mechanism  that  underlies  the  seasonal  regulation  of  pituitary  microvascular  remodelling.  
This  proved  to  be  a  conserved  mechanism  of  adaptation,  as  it  was  detected  in  both  short  
and  long  day  seasonal  breeders  (298) (41).  
The  pars   tuberalis   is   strategically   located  at   the   interphase  between   the  brain  and   the  
rest  of   the  pituitary.  Activation  of  melatonin   receptors   in  this   region  has  been  known   to  
affect  endocrine  output   from   the  pars  distalis   through  a  paracrine  mechanism  but,  until  
recently,   identification   of   the   effector   had   not   been   possible.   Indeed,   using   a  
hypothalamo-­pituitary   disconnected   animal   model,   it   became   apparent   that   melatonin  
can  potently  suppress  the  production  of  prolactin  secretion  within  the  pars  distalis  (162);;  
because   in   that   model   the   pars   tuberalis   is   completely   devoid   of   prolactin-­producing  
lactotroph  cells,  and  the  pars  distalis  does  not  contain  melatonin  receptors,  a  paracrine  
mode   of   action   was   warranted,   but   characterisation   of   the   signalling   factor   proved  
elusive.  The  melatonin-­induced  differential  expression  of  VEGF-­A   isoforms   in   the  pars  
tuberalis   not  only  underlies  seasonal   remodelling  of   the  pituitary  microvasculature,  but  
also  operates  as  a  paracrine  signal  to  regulate  the  endocrine  output  of  the  pars  distalis  
through  VEGF  receptors  present  in  endocrine  and  folliculostellate  cells  within  that  region  
(41).   In   sheep,   the   stimulation  of   the  anti-­angiogenic   isoforms  VEGF-­Axxxb  by   the   long  
duration   of   nocturnal   melatonin   exposure   characteristic   of   winter   potently   suppresses  
prolactin   secretion   without   direct   impairment   of   gonadotrophin   output   by   gonadotroph  
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cells,   leading   to   activation   of   the   reproductive   axis   and   enhanced   fertility.   In   contrast,  
stimulation  of   the  proangiogenic   isoforms  VEGF-­Axxx  by   the  short  duration  of  nocturnal  
melatonin  exposure  characteristic  of  summer  stimulates  prolactin  secretion  and  impairs  
gonadotrophin   output,   leading   to   blockade   of   the   reproductive   axis   and   infertility.   As  
prolactin   negatively   affects   the   gonadotroph   response   to   hypothalamic   stimulation   by  
gonadotropin   releasing   hormone   (GnRH),   the   melatonin-­induced   VEGF-­mediated  
regulation  of   the  gonadotrophic  axis  will   also  be  affected  by   the  VEGF-­A   regulation  of  
prolactin.   In  addition   to   its   role  during   lactation,  prolactin  has  a   variety  of   functions  as  
diverse  as  central  effects  to  reduce  anxiety  and  peripheral  effects  to  control  hair  growth  
and  molting.  Therefore,  the  VEGF-­A  regulation  of  endocrine  output  by  the  pituitary  gland  
can  play  a  major   role   in   seasonal   physiology.  Because   the   remaining   three  endocrine  
cell   types   of   the   pars   distalis,   i.e.   corticotrophs,   sommatotrophs   and   thyrotrophs   also  
posses   intimate   contacts  with  FSC  and   their   functions  display  annual   oscillations,   it   is  
highly   plausible   that   the   seasonal   control   of   the   response   to   stress,   growth   and  
metabolism   is   seemingly   mediated   by   a   VEGF-­dependent   mechanism   within   the  
pituitary.    
The  abundant  presence  of  VEGF-­producing  FSC   in   the  pituitary   infundibular  stalk,  and  
the  expression  of  VEGF   receptors   in   these  cells,   point   to  another  potential   role  of   this  
protein  family  in  the  control  of  seasonal  physiology.  Not  only  are  these  cells  adjacent  to  
the  melatonin  sensitive  pars  tuberalis  region  responsible  for  annual   time  measurement,  
but   also   in   close   contact  with   the  median   eminence  where   the   hypothalamic  neuronal  
axons  terminate  and  deliver  their  stimulatory  and  inhibitory  products  to  be  transported  by  
the  portal   system   to   the  pars  distalis.  Dynamic   structural  alterations   in  another   type  of  
glial  cells,  the  ependymal  tanycytes,  have  been  shown  to  facilitate  or  prevent  the  delivery  
of   hypothalamic   factors   in   the   median   eminence   through   retraction/protraction   of  
‘endfeet’  processes  that  operate  at  the  interphase  between  the  nerve  terminals  and  the  
fenestrated  capillaries  (219).  This  mechanism  has  been  shown  to  underlie  the  control  of  
seasonal  reproductive  cycles   in  birds  (296).  Moreover,   tanycytic  VEGF-­A  can  modulate  
the  plasticity  of  the  blood-­brain  barrier  at  the  level  of  the  hypothalamus (152).  As  VEGF-­
A  controls  fenestration  of  endothelial  cells  (226) (76),  and  also  functions  as  a  paracrine  
factor   to   relay  photoperiodic   information  to   the  pars  distalis,   it   is  possible   that  a  similar  
mechanism  operates  upstream,   i.e.   in  the  median  eminence,  to  transfer  seasonal  cues  
encoded   by   the   pars   tuberalis   to   the   brain.   Although   this   latter   alternative   requires  
experimental  corroboration,   it   is  clearly  apparent  that   the  melatonin-­induced  differential  
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expression  of  VEGF-­A   isoforms  within   the  pituitary  gland  plays  an  essential   role   in   the  
physiological  adaptation  to  the  seasonal  requirements  of  the  species  by  means  of  a  dual  
angiogenesis-­dependent  and  paracrine  mediated  mechanisms.  
  
Neuroprotection  
Of   the   VEGF   family   isoforms   VEGF-­A165   was   the   first   to   be   identified   as   a  
neuroprotective   factor   and   consequently   there   is   a   wealth   of   research   concerning   the  
neuroprotective  properties  of  VEGF-­A.  The  seminal  publication   identification  VEGF-­A165  
to  be  neuroprotective   for   adult  mouse  superior   cervical   ganglia   (SCG)  and  dorsal   root  
ganglia   (DRG)  explants,   cultured   in   serum-­free   conditions   (252).  Whole  DRG  explants  
cultured   in   the   presence   of   VEGF-­A165   had   a   reduced   number   of   terminal  
deoxynucleotidyl  transferase  dUTP  nick  end  labelled  (TUNEL)-­positive  neurons.  Further  
in   vitro   investigations  have   revealed  VEGF-­A165   and  mouse  VEGF-­A164   (homologue   to  
human  VEGF-­A165)   to   be   neuroprotective   for   primary   hippocampal   neurons  against   L-­
glutamic  acid-­induced  excitotoxicity  (25,  175),  hippocampal  neuroblastoma  cells  against  
serum   withdrawal   (129)   and   primary   cerebral   neuronal   cultures   against   serum   and  
glucose   withdrawal   (130).   The   endogenous   anti-­angiogenic   VEGF-­A   splice   variant  
VEGF-­A165b   that   only   partially   activates   VEGF   receptors(136)   is   also   able   to   elicit  
neuroprotection  for  hippocampal  and  dorsal  root  ganglion  neurons  [114]  
  
Sondell  et  al.   identified  a  Golgi-­like  distribution  of  VEGF-­A  immunoreactivity   in  ~30%  of  
small-­diameter  neurons  in  adult  mouse  dorsal  root  ganglia,  using  a  VEGF-­A  polyclonal  
antibody   able   to   bind   all   isoforms,   suggesting   that   VEGF-­A   is   synthesized   by   these  
neurons   (252).   VEGFR2   was   detected   on   most   neurons   (small   and   large   diameter)  
within   the  dorsal   root   ganglia.  This   suggests  VEGF-­A165a  and  other   splice   variants  are  
neuroprotective   for   DRG   neurons   in   an   autocrine   and   paracrine   manner   in   the   adult  
mouse  (252).  In  2001,  Oosthuyse  et  al.  demonstrated  a  neuroprotective  role  of  VEGF-­A  
in   vivo   consequently   unearthing   a   potential   therapeutic   role   for   VEGF-­A   in   the   motor  
neurodegenerative   disease,   amyotrophic   lateral   sclerosis   (ALS).   Mice   with   deletion   of  
the   hypoxia-­response   element   in   the   VEGF-­A   promoter   region   (VEGFd/d)   developed  
adult-­onset   progressive   motor   neuron   degeneration   reminiscent   of   ALS   (210).  
Furthermore,   cross   breeding   of   VEGFd/d   with   SOD1G93A   (ALS-­associated   human  
superoxide   dismutase-­1   mutation)   mice   produced   double   mutants   with   more   severe  
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weakness  and  reduced  survival  than  the  SOD1G93A  mutants  alone  (150).  SOD1G93A  mice  
have   reduced  VEGF-­A  and  VEGFR2  expression  levels   in   the  spinal  cord  suggesting  a  
role   in   disease   pathogenesis   (166)   and   administration   of   rhVEGF-­A164   protein  
(intraperitoneal   (302))   or   VEGF-­A165a-­expressing   lentiviral   vector   (14)   improved   motor  
deficits   and   survival   in   SOD1G93A   mice.   Storkebaum   et   al.   reported   that   intracerebro-­
ventricular   delivery   of   rat   VEGF-­A164   into   a   rat   model   of   ALS   delayed   the   onset   on  
paralysis,   improved  motor   performance   and   prolonged   survival   (257).   The   group   also  
identified   that   VEGF-­A165a   was   transported   in   an   anterograde   manner   and   preserved  
neuromuscular   junctions   in   these   mice   (257).   In   humans,   variations   in   the  
promoter/leader   sequence   of   the   VEGF-­A   gene   have   been   associated   with   reduced  
levels  of  circulating  VEGF-­A  and  this  has  been  reported  to  increase  the  risk  associated  
with  ALS  in  some  populations  (150).  On  the  contrary,  further  studies  have  not  found  an  
association   between   VEGF-­A   haplotypes   and   ALS   potentially   undermining   a   role   for  
VEGF-­A   in   the  human   (32,   33,   60,   276).   Nevertheless   the   apparent   aetiologic   role   of  
VEGF-­A   observed   in   mouse   models   of   ALS   and   other   types   of   neurodegeneration  
highlights   the   survival   role   VEGF-­A   plays   in   normal   health   and   has   provided   a   firm  
rationale   for   researching   the   therapeutic   potential   of   VEGF-­A   in   neurodegenerative  
diseases.  The  ability  of   transgenically-­expressed  neuronal  VEGF-­A165a  and  exogenous  
rhVEGF-­A165a   to   postpone   the   onset   of   ALS   complies   with   other   reports   of   VEGF-­
mediated  neuroprotection  but  the  mechanism(s)  protecting  motor  neurons  in  the  case  of  
SOD1G93A   mice   remain(s)   unresolved.   While   the   autocrine   and   direct   neuroprotective  
effects  of  VEGF-­A165a  are  well  documented,  it  is  not  known  if  the  in  vivo  neuroprotection  
shown  to  date  is  achieved  exclusively  by  direct  neuronal  interactions.  In  the  case  of  the  
murine   model   of   ALS,   transgenic   neuronal   overexpression   of   the   VEGF   receptor,  
VEGFR2,  also  prolongs  the  survival  of  SOD1G93A  mice  (257).  Furthermore,  VEGF-­A165a  
prevented  axonal  degeneration  and  activation  of  apoptotic  factors,  such  as  caspase-­3,  in  
cultured  motoneurons  transfected  to  overexpress  SOD1G93A  (166).  These  results  support  
the   hypothesis   that   VEGF-­induced   neuroprotection   observed   in   vivo   is   mediated  
primarily   by  a  direct   neuronal   interaction.  Further   research  has  been  documented   that  
supports   this   hypothesis,   by   disproving   a   significant   effect   of   VEGF-­A165a   on  
angiogenesis,   therefore   suggesting  VEGF-­A165a  protected  neurons   from   ischaemic   cell  
death   by   a   direct   action   (260,   286).   Therefore,   there   is   clear   evidence   that   direct  
application  of  VEGF-­A165a  to  neurons  is  neuroprotective  both  in  vivo  and  in  vitro.  
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Ameliorating  neurovascular  perfusion  deficits  
Motoneurons  are  vulnerable  to  ischaemia  (151)  suggesting  that  chronic  neural  perfusion  
deficits  may  underpin  the  development  of  neuronal  damage,  and   in   time   lead  to  adult-­
onset   neurodegeneration.   In   the   spinal   cord   of   VEGFd/d   mice,   VEGF-­A   levels   are  
reduced  by  25%  and  angiogenesis  is  not  impaired,  as  measured  by  capillary  density,  yet  
neural  perfusion  is  deficient  causing  chronic  ischaemia  of  motoneurons  (210).  Delivery  of  
plasmid  hVEGF-­A165a  gene  transfer  preserved  neural  function  in  rats  with  streptozotocin-­
induced   diabetes   by   preventing   regression   of   the   vasa   nervorum   (small   arteries   that  
supply   peripheral   nerves),   resulting   in   restoration   of   peripheral   nerve   function   (238).  
These  experiments  suggest  that  as  well  as  a  direct  neuroprotective  effect  VEGF-­A  may  
also  promote  neurovascular  perfusion  thereby  having  an  indirect  neuroprotective  effect.  
VEGF-­A  in  PNS  neuroprotection  and  pain  
The  involvement  of  VEGF-­A  in  regulation  of  other  physiological  systems  has  come  to  the  
fore  primarily  due   to   the  entwined   roles  of   the  vasculature  and  other  systems,  and   the  
emerging   role  of  VEGF-­A   in   the   somatosensory  system   is  a  good  example(223,  264).  
The  somatosensory  system,  whereby  the  primary  afferent  sensory  neurons  which  detect  
and   transmit   sensory   signals   to   the   central   nervous   system,   is   deemed   to   be   highly  
dependent  upon  blood  supply.  In  times  of  peripheral  limb  ischaemia  this  sensory  nerve  is  
damaged  due  lack  of  nutritional  supply  and  consequently  sensory  perception   is  altered  
and   pain  manifests(265).   During   times   of   traumatic   nerve   injury   or   stress   the   sensory  
nervous  system  becomes  sensitised  (117),  primarily  due  to  altered  expression  profiles  of  
voltage   gated   channels   and   growth   factors(269).   Further   instances   by   which   pain  
manifests   include   diabetic   neuropathic   pain,   chemotherapy   induced   neuropathic   pain  
and  arthtritis.  Sensory  neurons  are  dependent  upon  a  vast  array  of  growth  factor  families  
e.g.   nerve   growth   factor   for   development,   survival   and   function.   There   is   now  
accumulated  evidence  demonstrating  a  strong  role  for  VEGF-­A  dependent  actions  of  the  
sensory  neuron.  
  
VEGF-­A  was  initially  associated  with  sensory  neuronal  function  in  the  early  2000s  ((252)  
(250)).  These  studies  demonstrated   that   the  expression  of  VEGF-­A  and   receptors  was  
evident   in  the  sensory  neurons  of   the  dorsal   root  ganglia   (DRG)   (251)  but  additionally,  
VEGF-­A   had   strong   neuritogenic   actions;;   driving   neuronal   survival   (251)   and  
regeneration(253).  These  neuroprotective  attributes  were  only  initially  used  in  vivo  in  the  
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mid  2000s  (190,  227)  to  prevent  in  animal  models  of  diabetic  neuropathy.  These  studies  
used  the  cytoprotective  and  regenerative  capabilities  of  VEGF-­A  as  diabetic  neuropathy  
is   known   to  be  associated  with   ischaemia  and  associated   neuronal   damage.   VEGF-­A  
treatment   prevented   nerve   fibre   loss   and   reduced   substance   P   and   calcitonin   gene  
related   peptide   release(44).   Interestingly   studies   further   utilising   these  neuroprotective  
actions   to   initiate   recovery   following   spinal   cord   injury   demonstrated   that   VEGF-­A  
administration   locally   to   the   spinal   cord   induced   regeneration   of   spinal   cord   (195),  
however   this   neuritogenic   action   was   associated   with   alterations   in   nociceptive  
behaviour.  Nesic  and  colleagues  demonstrated  that  VEGF-­A  administration  to  the  spinal  
cord   led   to   a   persistent   mechanical   allodynia   (195)   In   contrast   Van   Neerven   et   al.  
observed   that   VEGF-­A   attenuated   the   development   of   mechanical   allodynia,   not   to  
thermal(274).   Additional   studies   following   an   insult   to   nervous   system,   in   this   case  
chronic  constriction   injury   to   the   sciatic  nerve   that   induces  neuropathic  pain  behaviour  
was  associated  with   increased  expression  of  VEGF-­A  and  VEGFR2   in   the  dorsal   root  
ganglia  sensory  neurons  and  dorsal  horn  of  the  spinal  cord(163).  Isolating  DRG  sensory  
neurons,  and  incubating  with  VEGF-­A,  demonstrates  a  pronounced  activation  of  sensory  
neurons  (163)  (170).  Interestingly,   in  support  of   the  pro-­nociceptive  actions  of  VEGF-­A,  
administration   of   anti-­VEGF-­A   (161)   or   VEGFR   inhibitor   (vatalanib)   (163)   resulted   in  
attenuation   of   neuropathic   pain   behaviour.   This   has   become   widely   recognised,   with  
VEGF-­A  induced  pro-­nociception  mediated  by  VEGF-­A  activation  of  C  fibre  nociceptors  
and  modulation  of  non  canonical  TRP  channel   activity;;  TRPV1   (118,   170)  and  TRPA1  
(119)  activity.  Additional  work   complements   this  work  by   identifying  VEGF-­A  signalling  
induces  inflammatory  arthritis  (98)  and  cancer  pain(242).  This  would  support  the  concept  
that   anti-­VEGF-­A   or   VEGF   receptor   inhibitory   agents   would   be   strong   candidates   for  
analgesic  development  and  application  in  a  multitude  of  disease  states.  
  
These   studies   highlight   a   strong   role   for   VEGF-­A   in  modulating   nociception   through   a  
prominent   pro-­nociceptive   action   (inducing   pain).   However   in   human   studies,   patients  
treated  with  anti-­VEGF-­A  therapy  suffer  from  intensified  sensory  neuropathy  (174).  Work  
by   Verheyen   et   al.   investigated   the   neuroprotective   actions   further   by   exploring   the  
rationale  that  anti-­VEGF-­A  treatment  in  association  with  cancer  treatment  induced  pain.  
Suppression   of   VEGF-­A   is   a   key   candidate   to   treat   cancer   though   many   treatments  
impact  upon  other  systems  in  leading  to  off  target  adverse  events.  This  includes  sensory  
neurons  to  which  suppression  of  VEGF-­A  signalling  initiates  neurodegeneration  and  pain  
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development   (281),   highlighting   that   endogenous   VEGF-­A   signalling   is   necessary   for  
normal  sensory  neuronal  survival  and  to  regulate  nociception.  This   is   in  contrast   to  the  
majority  of   those  publications  previously  discussed.  Further   interpretation  was   required  
to  explore  VEGF-­A  function  in  nociception.  
  
The  c-­terminal   splice   variant   of  VEGF-­A,  VEGF-­A165b   (exon  8b   containing),  which  had  
been  shown  to  be  anti-­angiogenic  was  found  to  be  expressed  in  the  nervous  system(20).  
It  is  worth  noting  that  all  investigations  into  VEGF-­A  and  nociception  until  this  point  had  
concentrated  on  the  archetypal  VEGF-­A  isoforms  (43).  Subsequent  work   identified  that  
VEGF-­Axxxb  was   cytoprotective,   protecting  DRG  sensory   neurons   from   traumatic   (25),  
chemotherapy  (25,  279)  and  hyperglycaemia  (119)  induced  nerve  injury,  and  that  these  
actions   were   mediated   by   VEGF   receptor   2   (25,   119).   Through   investigation   of   this  
alternative   splice   variant   allowed   for   VEGF-­A   mediated   neuronal   functional   to   be  
deciphered.  It  was  discovered  that  inhibition  of  VEGF-­A  signalling  in  the  primary  afferent  
c   fibre   nociceptor   led   to   development   of   pain   (118)   in   support   of   Verheyen   and  
colleagues.   However,   it   was   determined   that   VEGF-­Axxxb   isoform   was   predominantly  
expressed   in   normal   uninjured   nervous   tissue   (118,   120)   highlighting   that   in   normal  
animals  inhibition  of  VEGF-­A  signalling  would  be  suppressing  predominantly  VEGF-­Axxxb  
function.   This   is   of   importance   as   VEGF-­A165b   administration   is   antinociceptive,  
increasing  withdrawal   threshold   in  naïve  animals   (DRG   (118)  and  spinal   cord(120))   so  
suppression   of   endogenous  VEGF-­A   signalling  would  be   inhibiting  an   anti-­nociceptive  
signalling   pathway   thus   driving   pain.   Further   investigations   elucidated   that   VEGF-­Axxx  
isoforms   are   pronociceptive   (118,   120)   and   that   VEGF-­A165b   treatment   attenuated  
VEGF-­A165   mediated   sensitisation   of   C   fibre   nociceptors   and   consequently   pain  
development  (118).  Further  pathological  conditions  such  as  during  traumatic  nerve  injury  
the   expression   profiles   of   these   isoforms   switch,   with   the   pronociceptive   VEGF-­Axxx  
predominating   in  DRG  sensory  neurons  with  VEGFR2   activated,   initiating   neuropathic  
pain  development(118).  Administration  of  VEGF-­Axxxb  in  these  rodent  models  of  chronic  
pain  attenuates  pain  development  (118-­120).  
Understanding   VEGF-­A   mediated   nociception   has   allowed   a   greater  
interpretation  of  the  impact  that  VEGF-­A  has  upon  the  sensory  nervous  system.  Defining  
the  opposing  actions  of  VEGF-­A  isoforms  provides  a  powerful  opportunity  to  investigate  
novel   tools  to  manipulate  pain  systems.  Alternative  splicing  of  VEGF-­A  family   is  known  
to  be  dependent  on  key  splicing  factors  to  drive  preferentially  distinct  expression  profiles,  
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for  example  selecting  exon  8a  or  exon  8b  containing  isoforms.  In  terms  of  pathology  e.g.  
retinopathy(215)   and   cancer(6),   it   was   identified   that   SRPK1   drives   VEGF-­Axxx  
preferential  expression.  Consequently   it  was  determined   that  SRPK1-­SRSF1  signalling  
was  a  key  regulator  of  VEGF-­Axxx  expression  in  the  sensory  nervous  system  and  a  key  
factor   in  chronic  pain  development  (118,  120).  Through  manipulation  of  SRPK1  activity  
through   pharmacological   inhibition   allowed   the   suppression   of   VEGF-­Axxx   mediated  
pronociception  therefore  chronic  pain  was  attenuated  (118,  120).  Investigations  into  this  
area  has  allowed   for   the  expansion  of  not  only  how  VEGF-­A   is   involved   in  nociception  
and   chronic   pain   but   has   also   initiated   work   into   the   development   of   new   analgesic  
regimens  that  may  prove  highly  beneficial  in  treating  chronic  pain.    
VEGF  in  neurogenesis,  learning  and  memory    
Angiogenesis   and   neurogenesis   have   long   been   linked   both   spatially   and  
mechanistically  (165).  Neurogenesis  was  first  linked  to  learning  and  memory,  particularly  
spatial   memory,   in   the   1990s   through   observations   of   experience-­dependent  
hippocampal  growth  and  neurogenesis   in  birds  and  mammals   (154).  Adult  mammalian  
neurogenesis   occurs   primarily   in   the   subgranular   layer   of   the   dentate   gyrus   and   the  
subventricular   zone,   from   where   neurons   migrate   to   the   olfactory   bulb   (63).  
Neurogenesis  has  also  been   found,  albeit   to  a   lesser  extent  and  potentially  only  under  
non-­physiological   conditions,   in   other   neocortical   regions,   the   striatum,   amygdala   and  
substantia  nigra  (63).      
The  contribution  of  VEGF  to  central  neuronal   function,  specifically  neurogenesis  
and   neuroprotection,   and   subsequently   to   hippocampal   neurogenesis   was   also  
recognised   at   a   relatively   early   stage   (128),   largely   due   to   this   relationship   between  
neurogenesis  and  angiogenesis    
While  there  has  been  considerable  debate  on  the  link  between  neurogenesis  and  
hippocampal   learning   and   memory   it   is,   however,   clear   that   CNS   neurogenesis   can  
result   from   direct   effects   of   VEGF-­A   on   neuronal   progenitor   cells   (128),   rather   than  
through   an   indirect   effect   on   angiogenesis.   VEGF-­A   is   secreted   by   subgranular   zone  
neuronal   progenitor   cells  where   it   acts   to   control   proliferation   (143).  Here  endogenous  
VEGF-­A   affects   the   proliferative   function   of   neuronal   stem/progenitor   cells,   without  
influencing  the  vasculature,  and  thus  can  directly  control  neurogenesis  (143).    
As   long-­term   potentiation,   a   well-­characterised   and   studied   type   of   synaptic  
plasticity   that   contributes   to   memory   formation,   also   stimulates   hippocampal  
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neurogenesis,  the  hypothesis  evolved  that  VEGF-­A  could  be  involved  in  normal  learning  
and  memory.  Whether   there   is   a   causal   link  between  hippocampal  neurogenesis,  LTP  
and  learning/memory  has,  however  been  debated  (155,  160).  There   is  strong  evidence  
for   effects   of   VEGF-­A   on   neurogenesis,   including   its   association   with   exercise(78),  
environment   (39,   66),   vascular   perfusion/angiogenesis   (39),   direct   effects   on   synaptic  
function   and  NMDA   receptors   (58),   and  associations  between  VEGF-­A   and   long   term  
potentiation,   and   learning   and   memory   (202).   There   are   also   indications   from   clinical  
(186)  and  preclinical  (214)  studies  that  VEGF  receptor  blockade  may  affect  learning  and  
memory,  and  other  cognitive  functions,  but  strong  causal   links  have  been  more  difficult  
to  demonstrate.  Recent  elegant  studies  in  which  reversible  VEGF-­A  gain-­of-­function,  and  
loss-­of-­function   studies  were  done  using   inducible   transgenic   lines  have   been   able   to  
separate  effects  on  the  neurogenesis,  vascular  structure  and  learning  and  memory.  Loss  
of  VEGF-­A  had  detrimental  effects  on  memory,  without  notable  effects  on  neurogenesis  
or   vascular  density  or  perfusion.   Importantly   the  positive  effect   of  VEGF-­A  on  memory  
was  evident  before  any  maturation  of  new  neurons,  again  separating  effects  on  learning  
and  memory  from  neurogenesis  (159).  
The  evidence  for  an  involvement  of  VEGF-­A  in  cognitive  function,  particularly   in  
learning   and  memory   is   now   compelling.   This   has   important   implications   for   VEGF-­A  
function   in   normal   ageing   (110),   depression/anxiety   (47)   and   neurodegenerative  
diseases  such  as  Alzheimer’s  disease  (110)  
  
VEGF  and  immune  function  
Control  of  endothelial  adherence  
A   key   regulatory   component   of   endothelia-­circulatory   cell   adhesion   is   the   endothelial  
intraluminal   surface   layer,   the   glycocalyx,   a   dense   layer   of   transmembrane   and  
membrane-­bound  molecules(49).  The  glycocalyx  is  reported  to  range  in  thickness  from  
~200  to  2000nm  depending  on  the  tissue  bed  and  this  range  is  significantly   larger  than  
the   ~10nm   span   of   adhesion   molecules   and   receptors(26,   208).   Consequently   a  
decrease   in  glycocalyx  aids  platelet  and   leukocyte  adhesion(49),  and  one  of   the  many  
effects   of   VEGF-­A165   on   endothelial   cells   is   to   decrease   the   thickness   of   the  
glycocalyx(221).   Conversely   treatment   with   the   VEGF   receptor   partial   agonist   VEGF-­
A165b   in  vivo  can  rescue  disease-­associated  glycocalyx   loss(208).  VEGF-­A165   treatment  
of   endothelial   cells   also   alters   expression   of   key  molecules   and   receptors   involved   in  
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circulatory   cell   adhesion   and   leukocyte   transmigration   through   endothelia.   P-­   and   E-­
selectin   endothelial   expression   is   modulated   by   VEGF-­A(221,   261).   P-­selectin  
glycoprotein   ligand-­1   (PSGL-­1)   is   the   natural   ligand   of   both   P-­   and   E-­selectin   and   is  
expressed   by   nearly   all   leukocytes.   Von   Willebrand   Factor   (vWF)   is   another   key  
molecule   in   the  adhesion  of   leukocytes  and  platelets  to   the  endothelium  and   treatment  
with  VEGF-­A165  promotes  vWF  expression(22).  While  the  selectin  receptors  are  strongly  
associated   with   the   initial   capture   and   rolling   stages   of   leukocyte   adhesion,   vascular  
cellular  adhesion  molecule-­1  (VCAM-­1)  and  intercellular  adhesion  molecule-­1  &  (ICAM-­
1)   have   a   greater   role   in   mediating   firm   adhesion   and   the   initiation   of   transmigration  
across   the   endothelium.   VEGF-­A   also  modulates   endothelial   expression   of   these   key  
integrin-­binding  adhesion  molecules(80,  182,  233).    
VEGF-­A   causes   changes   in   endothelial   permeability   through   promoting   canonical  
transient   receptor  potential   (TRP)  TRPC6-­mediated  Ca2+  entry  and   in  doing   so   further  
contributes  to   leukocyte  transmigration  across  the  endothelium.  The  rise   in   intracellular  
Ca2+   drives  phosphorylation   changes  within   the  VE-­cadherin-­catenin   complex,   triggers  
actomysoin-­mediated   contractions   that   pull   on   endothelial   junctions   and   activates   the  
lateral  border   recycling   compartment(187,   284).  The   interaction  of   leukocytes  with   cell  
surface   molecules   triggers   intracellular   Ca2+   signals,   which   can   originate   from   the  
endoplasmic  reticulum  or  through  PECAM-­1  (CD31)-­mediated  TRPC6  channel  activity.    
VEGF-­C  can  promote  VCAM-­1-­mediated  adhesion  to  lymphatic  endothelium  by  inducing  
endothelial   expression  of   integrin  α4β1   (a.k.a.   very   late  antigen-­4,  VLA-­4)   in   lymphatic  
vessels(90).   VLA-­4   is   a   natural   ligand   for   VCAM-­1,   so   VEGF-­C-­can   also   act   as   an  
adhesive   ligand   that   adheres   to   vascular   cell   adhesion   molecule-­1   (VCAM-­1)-­positive  
metastatic  tumor  cells,  thereby  promoting  lymph  node  metastasis  (89).  There  is  also  now  
incrasing   evidence   that   VEGF   can   regulate   the   transmigration   of   T   cells   from   the  
circulation  into  areas  of  antigenic  presentation,  for  instance  in  tumours.  This  process  has  
been   linked   to   the   expression   of   chemokine   receptors   on   endothelial   cells,   and   a  
downregulation   of   CXCL10   has   been   implicated   in   preventing   tumour   specific   T   cells  
from  being  able  to  recognise  endothelial  cells  in  tumours.  (115)  (reviewed  in  (184))  
  
The  monocyte  as  a  VEGF  target  
VEGFR1   is   expressed   in   the   myeloid   progenitor   populations   (59)   and   is   therefore  
present   on  monocytes   and   appears   to   be   actively   involved   in   pro-­migratory   signalling  
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(18,   140).   Furthermore  maturation   and   differentiation   of   monocytes   into  macrophages  
increases  expression  of  soluble  forms  of  VEGFR1  (sVEGFR1)  (77,  144)  which  appears  
to   demonstrate   anti-­angiogenic   behaviour   (144).   VEGFR2   has   been   reported   to   be  
expressed   by   a   small   subset   of   Tie-­2   expressing   monocytes   (TAM),   although   the  
functional  significance  of  this  remains  undetermined  currently  (280).  PIGF  is  also  a  high  
affinity   ligand   for  VEGFR1   (211),  and  blockade  of  PIGF   (through  use  of   a  neutralising  
antibody)  is  sufficient  to  prevent  monocyte  infiltration(13,  82,  100).  Consequently  there  is  
functional   evidence   to   support   a   signalling   role   of   VEGFR1,   even   in   the   absence   of  
VEGFR2   in   most   monocyte   cell   populations.   However,   VEGF-­A   independent  
angiogenesis   following   anti-­VEGF-­A   treatment   has   been   reported,   induced   by  
mobilisation,   retention   and   angiogenic   activity   of   CD11b+Gr1+   myeloid   cells,   via   Bv8  
expression   (245,   246).   Further   experiments   demonstrated   no   role   for   PIGF   and  
subsequently   VEGFR1   in   myeloid   mediated   angiogenic   relapse   (245).   Consequently,  
although   recruited  monocytes/macrophages   release   a   host   of   proangiogenic   cytokines  
(including   VEGF),   and   respond   to   VEGF,   it   remains   undetermined   whether   or   not  
targeting   VEGF-­A   will   be   effective   at   also   blocking  monocyte  mediated   angiogenesis.  
However,  it  has  become  clear  that  monocyte  expression  of  VEGF  is  isoform  dependent.  
In   patients   with   metabolic   disease   (obesity   and/or   type   2   diabetes),   and   peripheral  
arterial   disease   (PAD)   peripheral   blood   mononuclear   cells   (PBMCs)   demonstrate  
increased   expression   of   VEGF-­A165b,   VEGF-­A189b   and   VEGF-­A121b(139).   This   is  
recapitulated  in  mice  treated  with  high  fat  high  sucrose  diets,  and  in  ob/ob  obese  mice.  
This   has   been   linked   to   increased   Wnt5a   signalling   in   the   monocytes,   as   monocyte  
specific   Wnt5a   gain   of   function   mice   also   have   increased   VEGF-­A165b   after   arterial  
ischemia(139).  The  mechanisms  through  which  this  Wnt5a  dependent  monocyte  specific  
splicing   switch   from   pro-­angiogenic   VEGF-­A165a   to   anti-­angiogenic   VEGF-­A165b   in  
ischemic   conditions   is   not   known,   but   once   identified   could  be  a   potential   therapeutic  
approach  for  cardiovascular  disease.  
Conclusion  
Vascular  Endothelial  Growth  Factors,  despite  their  name,  act  beyond  the  vasculature,  on  
cells   other   than   endothelial   cells   and   can   act   in   ways   other   than   stimulating   growth.  
While  not   incorrectly  named  (they  can  act  as  vascular  endothelial  growth  factors)   their  
role   in   healthy   functioning   of   mammals   is   widespread   and   extensive,   affecting   most  
tissues  even  under  normal  circumstances.  This  review  is  not  exhaustive  of  the  functions  
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of  VEGFs  –  they  also  act  in  the  ovary,  the  endometrium,  the  heart,  the  renal  tubules,  and  
in  the  gut,   to  name  a  few  tissues  and  systems  that  we  have  not  covered,  and  they  are  
likely  to  have  many  as  yet  undiscovered  functions.  Moreover,  there  are  many  aspects  of  
the  topics  covered  here  that  are  not  covered  in  as  great  a  depth  as  we  would   like.  The  
contribution  of  VEGFs  to  disease  often  drives  the  research,  but  an  understanding  of  their  
role  in  physiology  is  also  of  critical  importance,  both  for  understanding  what  happens  in  
disease,   and   for   understanding   how  normal   physiology  works.   The   complexity   of   their  
regulation,  the  effect  of  the  different  genes  and  their  isoforms,  and  their  co-­ordination  are  
still   not   well   understood,   but   it   is   now   increasingly   clear   that   they   play   a   key   role   in  
homeostasis,  particularly  in  fluid  homeostasis  in  the  vasculature,  across  multiple  organs,  
and   sensory   and   somatosensory   systems   in   the   nervous   system,   as   well   as   in  
remodeling   situations   such  as   during  wound  healing  and   response   to   injury.   Although  
there  has  been  extensive  work  carried  out  over  the  years  on  the  involvement  of  VEGFs  
in   pathology,   perhaps   the   coming   decade  will   yield   significant   insights   into   the   role   of  
these   complex   and   fascinating   proteins   in   controlling   normal   function   in   mammals,  
including  humans.  
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Figure  Legends  
Figure   1.   Schematic  of   the  VEGF   receptors.  VEGFR1  and  VEGFR2  both  have   seven  
IgG  domains,   and  when   they  bind  VEGF  act   as  homodimers.  The   intracellular   domain  
contains   a   kinase   insert   domain,   and   the   receptors   can  heterodimerise.   VEGFR3   is  a  
similar  receptor  but   is  proteolytically  cleaved  during  synthesis,  and  held  together  with  a  
disulphine  bond  between  IgG  4  and  5.  The  co-­receptors  NP1  and  NP2  interact  with  the  
VEGF   receptors   to  aid   signalling,   intracellular   sorting   and   recycling   to   the  membrane.  
VEGF-­B   and   PlGF   both   bind   only   to   VEGFR1,   VEGF-­A   binds   both   VEGFR1   and  
VEGFR2   and   VEGF-­C   and   VEGF-­D   bind   to   VEGFR3,   but   when   proteolytically  
processed  increase  their  affinity  for  VEGFR2.    
  
Figure  2.   Splicing  of   the  VEGF-­A   gene.   The   8   exons   are   differentially   spliced   to   form  
multiple   isoforms   in  two  primary   families,   the  pro-­angiogenic  VEGF-­Axxx,  which  use  the  
proximal   splice   site   in   exon   8,   and   the   partial   agonist   VEGF-­Axxxb   family,   which   can  
prevent  VEGF-­Axxx  mediated  angiogenesis,  but  can  signal  to  prevent  cytotoxicity  through  
partial  activation  of  VEGFR2.    
  
Figure  3.  Coverage  of  endothelial  fenestrations  by  glycocalyx.  Induction  of  fenestrations  
has   been   shown   by   VEGF,   and   VEGF   knockdown   in   the   glomerulus   reduces  
fenestrations   in   glomerular   endothelial   cells.   The   endothelial   cells,   including   the  
fenestrations,   are   covered   with   a   glycocalyx   (imaged   in   A   using   electron   tomography  
transmission  electron  microscopy)   (9).  B.   In  diabetes   the  glycocalyx   is   lost,  but  can  be  
restored  by  treatment  with  VEGF-­A165b  (208).  
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